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Primaquine is an important antimalarial agent because of its activity against 
exoerythrocytic forms of Plasmodium sp. Methemoglobinemia and hemolytic anemia, 
however, are dose-limiting side effects of primaquine therapy. These hemotoxic effects 
are believed to be mediated by metabolites, though the identity of the toxic specie( s) and 
the mechanism underlying hemotoxicity have remained unclear. Previous studies 
showed that an N-hydroxylated metabolite of primaquine, 6-methoxy-8-
hydroxylaminoquinoline, was capable of mediating primaquine-induced hemotoxicity. 
The present studies were undertaken to investigate the hemolytic mechanism of 5-
hydroxyprimaquine (5-HPQ), a phenolic metabolite that has been detected in 
experimental animals. 
5-HPQ was synthesized, isolated by flash chromatography and characterized by NMR 
spectroscopy and mass spectrometry. In vitro exposure of 51er-Iabeled erythrocytes to 5-
HPQ induced a concentration-dependent decrease in erythrocyte survival (TC50 ~40 ~M) 
when the exposed cells were returned to the circulation of isologous rats. 5-HPQ also 
induced methemoglobin formation and depletion of glutathione (GSH) when incubated 
with suspensions of rat erythrocytes. Furthermore, when red cell aSH was depleted 
(>95%) by titration with diethyl maleate to mimic aSH instability in human glucose-6-
phosphate dehydrogenase deficiency, a 5-fold enhancement of hemolytic activity was 
observed. These data indicate that 5-HPQ also has the requisite properties to contribute 
to the hemotoxicity of primaquine. 
XlI 
To investigate the fate of erythrocytes in vivo after in vitro exposure to 5-HPQ, rat 
sler-Iabeled erythrocytes were incubated with hemolytic concentrations of 5-HPQ and 
then re-administered intravenously to rats. The time-course of loss of radioactivity from 
blood and uptake into the spleen and liver was measured. In rats given 5-HPQ-treated 
erythrocytes, an increased rate of removal of radioactivity from the circulation was 
observed as compared to the vehicle control. The loss of blood radioactivity was 
accompanied by a corresponding increase in radioactivity appearing in the spleen but not 
in the liver. When rats were pretreated with clodronate-Ioaded liposomes to deplete 
splenic macrophages, there was a decreased rate of removal of radioactivity from the 
circulation and a markedly diminished uptake into the spleen. A role for phagocytic 
removal of 5-HPQ-treated red cells was confirmed in vitro using the J774A.l 
macrophage cell line. Furthermore, depletion of red cell aSH with diethyl maleate 
significantly enhanced in vitro phagocytosis of 5-HPQ-treated red cells. These data 
indicate that splenic macrophages are responsible for removing 5 .. HPQ-treated red cells 
and support a role for depletion of aSH as a key event in the process leading to 
macrophage recognition and phagocytosis of 5-HPQ-damaged erythrocytes. 
To investigate the mechanism underlying the hemolytic activity of 5-HPQ, we have 
examined the effect of hemolytic concentrations of 5-HPQ on ROS formation within rat 
erythrocytes using the cellular ROS probe, 2' ,7' ... dichlorodihydrofluoresein diacetate 
(DCFDA). In addition, we examined the effect of 5-HPQ on membrane lipids and 
cytoskeletal proteins. The data indicate that 5-HPQ causes a prolonged, concentration-
dependent generation of ROS within erythrocytes. Interestingly, 5-HPQ-generated ROS 
was not associated with the onset of lipid peroxidation or an alteration in 
Xlll 
phosphatidylserine asymmetry. Instead, 5-HPQ induced oxidative injury to the 
erythrocyte cytoskeleton, as evidenced by changes in the normal electrophoretic pattern 
of membrane ghost proteins. Immunoblotting with an anti-hemoglobin antibody revealed 
that these changes were due primarily to the formation of disulfide-linked hemoglobin-
skeletal protein adducts. These data suggest that cytoskeletal protein damage, rather than 
membrane lipid peroxidation or loss of phosphatidylserine asymmetry, underlies the 
process of removal of erythrocytes exposed to 5-HPQ. 
Cummulati vely, the data presented in this dissertation describe a mechanism by 
which exposure to 5-hydroxyprimaquine leads to the hemolytic removal of red cells; i.e. 
the generation of intracellular oxidative stress causes protein oxidation and hemoglobin 
binding to the membrane and subsequent phagocytosis by macrophages. A relationship 
between drug-induced hemolytic anemia and mechanisms of red cell senescence is 
discussed, as are possible implications for the antimalarial therapeutic effect of 
primaquine. The relative contribution of N-hydroxy vs. phenolic metabolites to the 
overall hemotoxicity of primaquine remains to be assessed. 
CHAPTER! 
Background and Introduction 
Normal Red Cell Senescence 
Physiology 
2 
The mature red cell is a "marvel of functional design" that has been stripped of all 
organelles and nuclear material, leaving only a "wafer-shaped membranous bag of 
protein," 8}lm in diameter (Jandl, 1996). Human red cells are formed from progenitor 
cells in the bone marrow prior to being released into the circulation, where they begin an 
arduous journey of 100 to 200 total miles, which lasts approximately 120 days (-60 days 
in the rat). During this journey, each "membranous bag of protein" travels at an 
incredible rate, such that it passes through the heart once every 1 to 3 minutes, while 
squeezing through capillary channels as small as 3Jlm across and managing constant 
exposure to oxidative stress (Jandl, 1996). 
The red cell is perfectly engineered and well equipped to handle these normal 
stresses. However, certain changes are thought to accumulate on the red cell surface over 
its lifespan, which define the cell as "senescent" and lead to its uptake and degradation by 
resident macrophages of the reticuloendothelial system (RES) by 120 days (Rifkind, 
1966). Given the massive number of red cells our circulation (-43 trillion), the removal 
of 1/120th of the total number circulating erythrocytes every day represents a truly 
remarkable feat. Approximately 360 billion senescent red cells are removed from the 
circulation every day, amounting to almost 5 million red cells every second (Bratosin et 
aI., 1998). However, despite representing a very significant physiological event, the 
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specific changes that occur to the red cell and the mechanism(s) by which it is recognized 
and removed from the circulation are not well defined. 
Oxidative Stress in the Red Cell 
Red cells are ideally designed to deliver oxygen to the tissues. The hemoglobin (Hb) 
content of the red cell is approximately 5mM ("",,34 g/dl) with a heme-iron content of "",,20 
mM, representing "",,95% of total cellular protein, (Jandl, 1996). Such high hemoglobin 
concentrations allow the red cell to be highly specialized for the transport of oxygen and 
carbon dioxide between the lungs and tissues. However, it is this specialized capacity 
that also renders the red cell susceptible to chronic oxidative stress. 
Oxidative stress occurs in the red cell, because the exposure of its iron-rich contents 
to oxygen-rich environments leads to auto-oxidation of hemoglobin and subsequent 
formation of methemoglobin and hydrogen peroxide (Fig. 1.1). Thanks to the activities 
of several anti-oxidant enzymes, including superoxide dismutase, catalase, glutathione 
peroxidase and glutathione reductase, the red cell is adequately equipped to handle this 
stress under normal conditions. Methemoglobin is readily reduced to hemoglobin by the 
NADH-dependent methemoglobin reductase (Passon and Hultquist, 1972), and 
superoxide is converted to hydrogen peroxide by superoxide dismutase (Fridovich, 1975), 
which is then acted on by the catalase and glutathione peroxidase/reductase systems 
(Eaton, 1991) as follows: 
4 
° .!. + ° .!. + 2H+ SOD )II- H20 2 + 02 2 2 
2H20 2 
Catalase 11- 2H20 + 02 
2GSH + 2H20 2 
GSH Px .. 2H20 + GSSG 
GSSG GSH Red .. 2GSH 
Importantly, the actions of each of these enzymes (with the exception of superoxide 
dismutase) require the presence of NADPH as a cofactor. The only source of NADPH in 
the red cell is by generation from the pentose phosphate pathway, also called the hexose 
monophosphate (HMP) shunt (Fig. 1.2). The shunt acts by shuttling glucose-6-phosphate 
through several steps, the first two of which are oxidations that generate NADPH from 
NADP+. Normally the HMP shunt operates at only 3-5% of its maximum capacity, but 
when confronted with excess ROS generation through the pathway shown above or 
otherwise, the red cell responds by stimulating shunt activity (discussed below) and 
producing sufficient NADPH to deal with the stress. Any deficiency in this system or 
with the production of NADPH has devastating consequences for the ability of red cells 
to handle oxidative stress. 
Proposed Mechanisms of Red Cell Senescence. 
The mechanisms by which aged red cells are recognized and removed from the 
circulation are unclear. However, it is currently thought that oxidative damage in the red 
cell accumulates over time and leads to specific cell-surface changes, which mark the red 
cell for removal from the circulation, defining it as "senescent" (Bartosz, 1991). Many 
0+2 - 02 l1li( 
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Fig. 1.1. Normal production of active oxygen species within the red cell as a 
consequence of ferric iron-superoxide anion dissociation from oxyhemoglobin. Hb, 
oxyhemoglobin; MetHb, methemoglobin; SOD, superoxide dismutase; Gpx/GR, 
glutathione peroxidase/glutathione reductase. 
(Jollow and McMillan, 2001) 
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Fig. 1.2. Pentose phosphate pathway, or hexose monophosphate (HMP) shunt, of red 
cells. This cyclic pathway is activated by changes to cellular NADPINADPH ratios that 
favor NADP and accelerate the regeneration of NADPH, which is necessary for 
detoxification of ROS and the maintenance of GSH and cellular enzymes in a reduced 
state. The first, rate-limiting enzyme of the HMP shunt is G6PD. 
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studies have attempted to identify the precise target(s) of oxidative damage and to 
determine the mechanism(s) by which they lead to erythrophagocytosis by macrophages. 
The major hypotheses are: 1) that specific modifications to the red cell membrane result 
in the exposure of "senescence antigens" (protein, lipid, or carbohydrate) on the red cell 
surface that are recognized by circulating "senescence antibodies," which opsonize 
senescent red cells for phagocytosis (Kay, 1994); 2) that enzymatic removal of sialic 
acid residues from red cell glycolipids or glycoproteins results in recognition by a 
macrophage receptor (Bratosin et a!., 1998); 3) that red cell aging is analogous to the 
apoptotic response observed in other (nucleated) cell types, i.e. oxidative stress results in 
caspase activation and alterations to the normal asymmetric distribution of phospholipids 
in the membrane (MandaI et a!., 2002; Kuypers and de Jong, 2004); or 4) that protein-
protein interactions are necessary for recognition of "self," and oxidative damage alters 
these interactions among the cytoskeletal, integral membrane, and cell surface proteins 
(Oldenborg,2004). 
While each of these hypotheses is appealing, there is no consensus at present as to 
which represents the final erythrocyte death signal. It has been suggested that the 
mechanism of red cell senescence might not be able to be reduced to a single hypothesis, 
but that "when a metabolism or a cellular phenomenon is of vital importance it is always 
protected by multiple pathway systems" (Bratosin et aI., 1998). Much work remains to 
solve the molecular and cellular mechanism of erythrophagocytosis, but two hypotheses 
have arisen very recently that appear to be particularly relevant. 
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Phospholipid Asymmetry 
Phospholipid asymmetry was first established in the red cell, and most of what is 
known about its regulatory process was also discovered in erythrocytes. In all cell types, 
including normal circulating blood cells, an asymmetric conformation of membrane 
phospholipids is tightly regulated. Phosphatidylserine (PS) is actively and exclusively 
maintained within the inner leaflet of the plasma membrane and only becomes exposed to 
the outer leaflet in situations that require recognition and removal of damaged cells, Le. 
apoptosis, or initiation of the coagulation cascade (Kuypers and de Jong, 2004). 
Phosphatidy lethanolamine (PE) is also found within the inner leaflet, but it is not as 
tightly regulated as PS (Fig. 1.3). On the other hand, the choline-containing 
phospholipids, phosphatidylcholine and sphingomyelin, are found mainly in the outer 
leaflet of the plasma membrane. Three classes of integral membrane enzymes have been 
shown to be responsible for regulation of phospholipid asymmetry. Specifically, an ATP-
driven aminophospholipid translocase, also called "flippase," very efficiently transports 
PS and PE from the outer leaflet to the inner leaflet of the plasma membrane (Fig. 1.4), 
Additionally, a calcium-activated "phospholipid scramblase" causes non-specific 
bidirectional movement of multiple phospholipids, and an ATP-dependent "floppase," 
outwardly directs PC and cholesterol. 
It has been shown that PS exposure is one of the earliest detectable features in all 
apoptotic cells and facilitates recognition and removal of apoptotic bodies by 
macrophages expressing a PS receptor (Kuypers and de Jong, 2004). Additionally, 

















Fig. 1.3. Asymmetrical distribution of phospholipids in RBC membranes, shown as a 
percentage of total membrane phospholipid. PC, phosphatidylcholine; SM, 








Flippase Scramblase Floppase 
Fig. 1.4. Schematic representation of the action of lipid transporters in the plasma 
membrane. PC, phosphatidylcholine; SM, sphingomyelin; PS, phosphatidylserine; PE, 
phosphatidylethanolamine. "Flippase" (aminophospholipid translocase) is an ATP-
dependent transporter, which inwardly directs PS and PE. "Floppase" represents a class 
of ATP-dependent transporter, which transports PC and SM outwardly. "Scramblase" is 
an ATP-independent, Ca+2-activated transporter, which non-specifically disrupts 
phospholipids asymmetry via bidirectional transport. 
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of accumulation of malonyldialdehyde (MDA) following lipid peroxidation or damage to 
spectrin (Jain, 1984), as well as from non-specific Ca++·induced cell membrane 
scramblase activation (Bevers et aI., 1998). Interestingly, senescent red cells appear to 
retain portions of the apoptotic machinery and to also share the common apoptotic 
endpoint of PS exposure. MandaI et a1. demonstrated that procaspase 3 was converted to 
caspase 3 in red cells oxidatively damage by t-butyl hydroperoxide, which resulted in the 
exposure of PS and subsequent phagocytosis by macrophages (MandaI et aI., 2002). 
Although red cells lack mitochondria, it has been hypothesized that intracellular oxidative 
stress in the erythrocyte mimics the apoptotic response observed in nucleated cells, such 
that activation of caspase 3 negatively regulates flippase and causes extracellular 
exposure of PS (Bratosin et aI., 1997; MandaI et aI., 2002). These studies led to the 
suggestion that there may be a significant correlation between red cell senescence, 
oxidative stress and loss of phospholipid asymmetry. 
Protein-Protein Interactions and Recognition of "self" 
It has been proposed that normal protein-protein interactions among the cytoskeletal 
and integral membrane proteins of erythrocytes are necessary to confer the recognition of 
"self' to macrophages (Oldenborg et aI., 2000). CD47, i.e. integrin-associated protein 
(lAP), is a ubiquitously expressed transmembrane glycoprotein with five hydrophobic 
transmembrane-spanning domains and a short, alternatively spliced, hydrophobic tail. It 
was first identified in the placenta and neutrophil granulocytes as a protein that associates 
with u v f33 integrins, regulates integrin function and signals leukocyte responses to RGD-
containing extracellular matrices (Oldenborg, 2004). Like other cell types, red cells 
12 
express CD47; however, unlike other cell types, red cells do not express integrins, 
suggesting that there may be a unique role for this protein in erythrocytes. 
CD47 was demonstrated to be a marker of "self' in red cells, and this was 
hypothesized to represent a potential pathway for the expression of hemolytic anemia. In 
their initial study, Oldenborg et ai. showed that red cells from CD47 knockout mice were 
rapidly cleared when administered to the circulation of wild type mice (Oldenborg et aI., 
2000). Furthermore, they showed that CD47 on normal blood cells could prevent 
elimination by binding to the macrophage receptor, signal regulatory protein alpha 
(SIRPa), which is thought to send an inhibitory signal to the macrophages (Fig. 1.5). 
SIRPa contains intracellular immunoreceptor tyrosine-based inhibitory motifs (ITIMs), 
which become tyrosine-phosphorylated in response to CD47. ITIM phosphorylation 
causes the recruitment of the SH2 containing phosphatase (SHP-1) to the membrane, 
which subsequently inhibits tyrosine kinase-dependent signaling pathways thereby 
preventing phagocytosis (Oldenborg, 2004). Based on the finding that CD47 functions 
as a "marker of self' on erythrocytes, a role for CD47 in senescent red cells was 
explored. Several studies showed that aged murine red cells and stored or banked 
erythrocytes, which have been associated with increased clearance in vivo, both had 
reduced CD47 expression, supporting the hypothesis that phagocytosis of senescent red 
cells may be regulated by CD47-SIRPa interaction (Anniss and Sparrow, 2002; 
Oldenborg, 2004). 
CD47 is a member of the band 3 protein-based macrocomplex of integral and 
peripheral proteins in the red cell membrane (Bruce et aI., 2003). In its tetrameric form, 
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Fig. 1.5. Model for the regulation of erythrophagocytosis by the CD47/SIRPa system. 
Interaction of normal red cell CD47 with the macrophage SIRPa receptor results in 
tyrosine phosphorylation and subsequent recruitment of SHP-1 to the membrane, which 
negatively regulates phagocytosis by inhibiting downstream signaling. 
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Fig. 1.6. Schematic diagram of the band 3 macrocomplex. Tetramers of band 3 are 
attached to the spectrin cytoskeleton through ankyrin (band 2.1). Protein 4.2 binds 
ankyrin, band 3, and CD47, providing vertical attachment of CD47 to the cytoskeleton. 
CD47 is also horizontally associated with band 3 through the Rh proteins. 
(Bruce et aI., 2003) 
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and is the major attachment site of the red cell membrane to the cytoskeleton (Fig. 1.6). 
Given its importance for self-recognition, it is conceivable that oxidative damage to 
members of the band 3 macrocomplex, or CD47 itself, perhaps in the form of free 
sulfhydryl modification, could alter normal CD47-presentation to macrophages, resulting 
in a loss of self-recognition and phagocytosis. 
Drug-Induced Hemolytic Anemia 
Anemia, defined as a reduction in the concentration of circulating red cells, can occur 
from either a decrease in red cell production or from an increase in red cell destruction. 
Hemolytic anemia is the generic term used to describe the disease process that results 
from an increased destruction of red cells. Despite what the term "hemolytic anemia" 
might imply, frank red cell lysis in the circulation, i.e. "intravascular hemolysis," is 
relatively rare. Rather, the more common mechanism of destruction of red cells is due 
the recognition and phagocytosis of intact red cells by splenic macrophages, i.e. 
"extravascular hemolysis" (Jandl, 1996). Clinically, a decreased hematocrit causes 
hemolytic anemia patients to present acutely with fatigue, pallor, shortness of breath, and 
a rapid heart rate. As a result of hemoglobin catabolism, jaundice and dark urine also 
occur. Additional signs may include an increased spleen size, an increased reticulocyte 
count, and/or hemoglobinuria. 
A variety of drugs and environmental chemicals are known to cause hemolytic 
anemia, some of the more common of which are listed in Table 1-1. The "drug-induced 
hemolytic anemias" are collectively referred to as the Heinz body hemolytic anemias 
because of the "spheroidal inclusions of denatured hemoglobin that are a late sign of prior 
(JandI, 1996) 








































oxidation" (Borges and Desforges, 1967). While the exact mechanism by which the drugs 
listed in Table 1-1 cause the premature removal of damaged, but intact, red cells is 
unclear, the Heinz body hemolytic anemias tend to share some common characteristics: 
1) they are thought to occur following an initial oxidative stress, which results from free 
radical metabolites; 2) this oxidative stress is handled by the normal defense mechanisms 
of the cell, i.e. aSH peroxidase and catalase, which protect free sulfhydryl groups on Hb, 
SH-containing enzymes, membrane proteins, and membrane lipids; 3) aSH peroxidase 
and catalase, which are both dependent on NADPH, are eventually overwhelmed by this 
oxidative stress; 4) free radicals then attack various cellular targets, including 
hemoglobin, SH-containing enzymes, membrane protein, and/or membrane lipids; and 5) 
intracellular oxidative damage leads to cellular changes that are recognized by splenic 
macrophages and result in erythrocyte phagocytosis. While the precise mechanism by 
which intracellular oxidative damage is translated into an external cell-surface signal that 
marks the cell for removal is not clear, the common findings of oxidative stress and 
splenic sequestration have led to the hypothesis that drug-induced hemolytic anemia is 
due to an acceleration of the normal physiologic aging processes, whatever those 
mechanisms might be (Azen and Schilling, 1963; Tizianello et aI., 1968). 
Interestingly, there is some evidence available to suggest that there may be more than 
one mechanism by which hemolytic agents impose oxidative damage. Clinical studies by 
Degowin et al. (De go win et al., 1966) made an important distinction between the 
hemolytic effect of primaquine and another hemolytic drug, dapsone (Fig. 1.7). In their 
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Fig. 1.7. Effect of G6PD (A-) deficiency on the hemolytic activity of dapsone and 
primaquine in volunteers. PQ (Normal), primaquine in normal individuals; PQ (G6PD-
Def), primaquine in A- G6PD-deficient individuals; DDS (Normal), dapsone in normal 
individuals; DDS (G6PD-Def), Dapsone in A- G6PD-deficient individuals. 
(Degowin, 1966) 
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African (A-) variant G6PD deficient volunteers. In normal volunteers, dapsone was 
shown to be the more potent hemolytic agent. However, in the G6PD-deficient 
individuals (see below), primaquine was the much more potent hemolytic agent. 
Dapsone showed only a two-fold increase in toxicity in G6PD-deficient individuals, but 
the toxicity of primaquine was multiplied 30-fold. While the reason for the difference is 
unclear, it may be related to the fact that dapsone is metabolized to a single 
hydroxylamine-type metabolite that is hemolytic, whereas primaquine metabolism is 
complex with multiple non-toxic and toxic pathways (see below). Thus the hemolytic 
activity of primaquine may be mediated by the synergistic action of multiple toxic 
metabolites, including N-hydroxy-, quinoneimine- and quinone-types (see below). At a 
minimum though, the data show that there is marked variation in the hemolytic response 
to different agents, which suggests that more than one mechanism may be involved in 
drug-induced hemolytic anemia. 
Glucose-6-Phosphate Dehydrogenase Deficiency 
Historical 
The potential risk of hemolytic anemIa from use of the 8-aminoquinoline 
antimalarial-drug, pamaquine, was first reported in 1926. Observations over the next 30 
to 40 years, showed that pamaquine, and then later primaquine, were not universally 
toxic, but only caused hemolytic anemia in a subset of uniquely susceptible individuals, 
who were termed "primaquine sensitive." For normal individuals, pamaquine and 
primaquine (as well as many of the other drugs listed in Table 1-1) would cause 
hemolytic anemia only when given in very large doses, well above the therapeutic 
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window. However, "primaquine sensitive" individuals presented with hemolytic anemia 
even when receiving conventional therapeutic doses of primaquine. In response to these 
initial observations, extensive work was done in the 1950s and 1960s to elaborate the 
mechanism of "primaquine sensitivity," and those studies showed that the sensitivity was 
associated with an intrinsic abnormality in the red cell, which was later identified as an 
enzymatic defect of glucose-6-phosphate dehydrogenase, i.e. G6PD (Beutler et aI., 1955). 
Glucose-6-Phosphate Dehydrogenase, the enzyme 
G6PD is a cytosolic "housekeeping" enzyme that catalyzes the first and rate-limiting 
step of the pentose phosphate pathway (i.e. the hexose monophosphate shunt or HMP 
shunt), and in erythrocytes, this pathway is the sale source for NADPH. NADPH, in tum, 
is an important reducing cofactor for a variety of antioxidant enzymes, including catalase 
and GSH peroxidase/reductase (Fig. 1.2), which are necessary for the detoxification of 
ROS in the cell. 
The human G6PD monomer consists of 515 amino acids with a molecular weight of 
59.2 kDa (Beutler, 1994), but the active enzyme exists as a dimer that has binding sites 
for both glucose-6-phosphate and NADP. While the precise mechanisms of control for 
this important pathway are not yet completely understood, there appear to be at least two 
distinct roles for the cellular NADP/NADPH ratio (Jollow and McMillan, 2001). In 
addition to being a cofactor for the enzyme, NADP is necessary for conversion of the 
inactive G6PD monomer to the active dimer. Consequently, in the presence of high 
NADP concentrations, the conversion of monomer to dimer promotes G6PD, and hence 
HMP shunt activity (Jollow and McMillan, 2001). Conversely, NADPH provides a 
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potent inhibitory feedback control that is dependent on substrate (glucose-6-phosphate) 
concentration, such that the inhibition is greatest when the concentration of G6P is lowest 
(Yoshida and Lin, 1973). Under quiescent conditions, the NADPH/NADP ratio favors 
NADPH, hence these controls are estimated to limit the activity of normal G6PD to less 
than 1 % of the V max value of the enzyme (Yoshida and Lin, 1973). However, under 
enhanced oxidative stress conditions, NADPH is rapidly consumed and converted to 
NADP by the activities of catalase and GSH peroxidase/reductase. As the 
NADPH/NADP ratio drops, the inhibitory control of NADPH is diminished, and the 
activity of G6PD increases sufficiently to generate enough NADPH to handle the stress. 
Genetics 
G6PD-deficiency is an X-linked disorder, which, with several classes of variants, is 
considered to be the most common genetic deficiency in the world, affecting over 400 
million individuals worldwide (Beutler, 1994). Most of these variants are point 
mutations that result in a single amino acid change, which leads to loss of activity as the 
red blood cell ages (Beutler, 1990; Jollow and McMillan, 1998). Thus aged cells are 
thought to have decreased levels of active G6PD and are hence more susceptible to 
oxidative damage. G6PD deficient individuals include approximately 10% of African-
American males (A-variant) who have a residual G6PD activity that is approximately 
10% of normal. A- red cells that are older than 55 days are considered to have lost all 
activity. About 15% of Caucasians of Mediterranean descent (Med- variant), and 70% of 
Kurdish Jews, have a much more severe deficiency and red cells older than only 20 days 
are considered to have lost all activity. There are also population groups in Asia, India 
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and the Middle East that may express the same or other variants (Jollow and McMillan, 
1998). 
Forty-five years ago, several studies suggested that G6PD deficiency actually confers 
a resistance to falciparum malaria infection (Beutler, 1994), which has been postulated to 
have created a selective advantage for the G6PD deficiency in areas where malaria is 
endemic. The geographical correlation between a high prevalence of G6PD deficiency 
and areas where malaria is historically endemic is striking (Ruwende et aI., 1995). That 
G6PD deficiency is so common in those countries most affected by malaria complicates 
and significantly limits the use of drugs like primaquine in those countries where it is 
most needed. 
Malaria 
Malaria is a life threatening parasitic disease of epidemic proportions that is a major 
public health concern for developing countries. Every year, infection is responsible for 
300-500 million acute illnesses and an estimated 1.5-2.7 million deaths worldwide (Kain 
and Keystone, 1998). Tropical and subtropical regions with dense populations, typically 
the poorest in the world, are most affected but tend to be the least economically equipped 
to handle the severe disease burden or to contribute to the development of malarial 
treatment and prevention. Areas where malaria is considered to be endemic include: 
Africa, parts of Asia, Central and South America, Oceania and certain Caribbean Islands 
(Kain and Keystone, 1998). 
Malaria is a protozoan disease that is caused in humans by four different species of 
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Fig. 1.8. The life cycle of the malaria parasite (see text for details). 
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ovale, and P. malariae. The disease is characterized by extreme exhaustion associated 
with paroxysms of high fever, sweating, shaking chills and anemia. Malarial 
transmission occurs when an infected mosquito injects the malarial sporozoites into the 
bloodstream of a human host while taking a blood meal (Fig. 1.8). After a brief period of 
about 30 minutes, the sporozoites disappear from the bloodstream as they either migrate 
to the liver, where they infect hepatocytes, or are destroyed by phagocytes. Those 
sporozoites that infect hepatocytes form cyst-like structures and continue to develop and 
multiply during what is referred to as the "exoerythrocytic phase" of the parasite's 
development. This period can vary significantly depending on the malarial species 
involved. In particular, P. falciparum and P. malariae schizonts will develop directly into 
merozoites, but P. vivax and P. ovale schizonts are able to develop into hypnozoites as 
well as merozoites. The hypnozoite forms can remain dormant in the liver for months or 
even years before being reactivated into merozoites to continue the cycle, causing 
malarial fever spikes and chills long after the initial infection (Le. vivax malaria or 
"relapsing malaria"). The mechanism responsible for the reactivation of hypnozoites is 
unknown; regardless, the sporozoites eventually develop into merozoites and multiply 
until they overload the cell and force it to rupture. When rupture occurs, the merozoites 
are released into the bloodstream, where they infect red blood cells and initiate the 
"erythrocytic cycle." It is this cycle that is responsible for the severe fever spikes and 
chills typically associated with malaria infection. Similar to the exoerythrocytic cycle, 
the erythrocytic schizonts will eventually overload and rupture the red blood cell, 
releasing malarial forms that either reinfect other red cells to continue the cycle of fever 
spikes or develop into gametocytes, which are taken up by a new mosquito taking a blood 
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meal. The sexual phase of the malarial life cycle occurs in the mosquito and is completed 
when the mosquito injects sporozoites into a new host during another blood meal. 
Antimalarial Therapy. 
Historical 
Until the middle of the 20th century, malaria was endemic in parts of Europe and 
North America. Prior to the 18th century, the most accepted treatment for malaria was the 
so-called Gaelen method, which aimed to "expulse" the disease through "bleeding and 
purging". The first attempts at specifically treating malaria date back to the early 17th 
century when the bark of Cinchona trees from Peru was used. By the early 18th century, 
its use had become widespread, and in 1820, two French pharmacists isolated quinine as 
the active Cinchona bark ingredient. Quinine quickly replaced the crude bark for 
treatment of malaria and is credited with destroying the traditional expulsion methods of 
Gaelen. Over the next 100 years, demand for quinine increased, but the drug still had to 
be extracted from the Cinchona bark. As the world's overwhelming need for natural 
sources of quinine expanded, so did the search for more readily available synthetic drugs 
(Wernsdorfer and McGregor, 1988; Wiesner et al., 2003). 
In 1891, Paul Ehrlich cured two malaria patients with methylene blue, based on the 
observation that the dye was taken up by malarial parasites. By 1925, modification of the 
basic structure of methylene blue resulted in the synthesis of the first 8-aminoquinoline 
antimalarial compound, pamaquine. Unfortunately, pamaquine proved to be much too 
toxic and largely ineffective against P. falciparum. However, it did prove to be the first 
drug that was capable of preventing malarial relapse due to P. vivax. In 1932, mepacrine 
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(atebrine, quinacrine) was developed by attaching the basic side chain of pamaquine to 
acridine instead of quinoline. Mepacrine proved to be active against the erythrocytic 
stages of P. falciparum and was extensively used in combination with pamaquine during 
World War II. Studies by German scientists in the 1930s led to the synthesis of 
chloroquine, a 4-aminoquinoline blood schizontocide structurally derived from quinine 
that is effective for the treatment of both P. falciparum and P. vivax. Chloroquine 
quickly became the most effective and important antimalarial drug and was even used in 
several programs aimed at global eradication of malaria. Extensive studies in the 1940s 
then resulted in the development of most of the antimalarial therapies used today 
(Wernsdorfer and McGregor, 1988; Wiesner et aI., 2003). 
Malaria Chemotherapy and Drug Resistance 
Therapeutic regimens against P. falciparum, which typically consist of various 
combinations of blood schizontocides, have been very successful in the past. However 
extensive use these drugs, in particular the 4-aminoquinoline, chloroquine, has lead to 
increasing resistance throughout the world to almost all blood schizontocidal antimalarial 
agents currently used (Bjorkman and Phillips-Howard, 1990; White, 1998). Plasmodium 
falciparum resistance to chloroquine was first encountered within 15 years of its 
introduction and has steadily expanded ever since (Peters, 1987). Today, chloroquine is 
used primarily to treat malaria only in Central America, Haiti, the Dominican Republic 
and most of the Middle East; while malarial infection in every other endemic region of 
the world (Africa, Asia, and parts of the Middle East) is considered to be chloroquine-
resistant. Additionally, chloroquine-resistant parasites have become resistant to other, 
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sometime chemically unrelated drugs, such as qUInIne, mefloquine, proguanil, and 
pyrimethamine, among others. Because of this increased resistance, quinine has actually 
re-emerged as a drug of choice, but only in combination with other drugs. The latest 
search for an effective drug has lead to artemisinin and its derivatives, compounds 
derived from the ancient Chinese herbal qinghao and its active ingredient qinghaosu. No 
resistance has yet developed against the artemisinins, but the potential is thought to exist 
(Krishna et aI., 2004). Importantly, none of these drugs have been shown to be effective 
against relapsing P. vivax and P. ovale malaria. 
As is shown in Table 1-2, the development of antimalarial therapies has mainly 
concentrated against the erythrocytic cycle, while primaquine remains the only tissue 
schizontocide approved for the radical cure of latent tissue stages of malarial parasites. 
Additionally, no significant resistance has developed against primaquine; it continues to 
be effective against the latent tissue stage of all four human malarial species and for the 
treatment and prophylaxis of the most lethal species, P. falciparum (Shanks et aI., 2001). 
Primaquine thus has the potential to provide an important tool to combat malarial 
transmission and resistance, if something can be done to control its side-effects. 
Primaquine 
Primaquine (6-methoxy-8-[4-amino-1-methylbutylamino]quinoline; Fig. 1.9) is the 
prototype 8-aminoquinoline antimalarial drug. It was one of three drugs (pentaquine, 
isopentaquine and primaquine) that were developed during the Second World War by the 
antimalarial research initiative of the US Army that were shown to be more effective 
against vivax malaria than pamaquine but less toxic. Of these three drugs, primaquine 
Table 1-2. Current Drugs for Antimalarial 






























remains the most effective available compound for elimination of the hypnozoite stages 
of P. vivax and P. ovale (Wernsdorfer and McGregor, 1988). However, despite its unique 
importance for antimalarial therapy for over fifty years, the mechanism of therapeutic 
action of primaquine remains unknown. Limited data suggests that possible targets might 
include the parasitic inner mitochondrial membrane, dihydroorotate synthase, or DNA 
(Howells et aI., 1970; Boulard et aI., 1983; Peters, 1984). It has also been suggested that 
primaquine is converted to redox active metabolites in the liver, which contribute to the 
antimalarial activity of primaquine by generating reactive oxygen species (Bates et aI., 
1990), although direct evidence for this postulate is lacking .. 
Primaquine is effective against the latent tissue forms of all four human malarial 
species and has been gaining use for both the treatment and prophylaxis of P.falciparum 
in addition to the relapsing species (Shanks et at, 2001). Interestingly, primaquine is also 
useful when combined with clindamycin for the treatment of Pneumocystis carinii 
pneumonia (PCP), an infection that is common in immunosuppressed individuals and 
definitive for the conversion of HIV to AIDS, another worldwide epidemic (Toma et aI., 
1998). However, despite its importance and unique therapeutic effectiveness, use of 
primaquine is limited by its toxicity in G6PD deficient individuals, which, along with 
multi-drug resistance to most of the blood schizontocides, highlights the need for more 
effective antimalarial drugs with higher therapeutic ratios. 
Primaquine Metabolism. 
Previous studies have shown that redox-active metabolites rather than the parent drug 
are responsible for causing the major toxicities of primaquine, and possibly its 
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therapeutic effects as well. Primaquine is rapidly absorbed with a bioavailability of 96% 
in humans but is rapidly and extensively metabolized, resulting in removal of less than 
2% of the administered dose by renal excretion (Mihaly et al., 1985). However, little is 
known about the metabolic fate of primaquine, since the extraction, identification and 
quantification of the major redox-active metabolites has been significantly complicated 
by their instability and poor organic solubility (Idowu et aI., 1995). 
Despite the difficulty in identifying metabolites, the metabolism of primaquine is 
thought to be complex and involve oxidation to both the aminoquinoline ring and the 
alkylamino side-chain (Fig. 1.9). Carboxyprimaquine (PQ-CX) is formed by oxidation 
of the terminal carbon of the side chain, and was found in the plasma of humans and rats 
in concentrations significantly higher than the parent compound (Mihaly et aI., 1985). 
Although PQ-CX is the most abundant metabolite detected, it is neither redox active 
itself, which was shown by its inability to stimulate HMP shunt activity or form 
methemoglobin in red cells (Link et aI., 1985; Baird et aI., 1986); nor does it appear in 
the urine, which indicates further metabolism prior to excretion (Mihaly et aI., 1984). 
The only other human metabolite of primaquine that has been detected is the N-
dealkylated derivative, 6-methoxy-8-aminoquinoline or MAQ (Baty et aI., 1975), which 
was also unable to stimulate HMP shunt activity or cause methemoglobin formation 
(Link et aI., 1985; Baird et aI., 1986). Recently, our laboratory used human and rat liver 
microsomes to show that MAQ could be metabolized in vitro to MAQ-NOH, which was 
subsequently shown to have significant hemolytic activity (Bolchoz et aI., 2001). Other 
than these three metabolites (PQ-CX, MAQ, and MAQ-NOH), no other human 
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Fig. 1.9. Putative pathways of primaquine metabolism. PQ-NOH, N-hydroxy-
primaquine; PQ-CX, 8-(3-carboxy-1-methylpropylamino )-6-methoxyquinoline; MAQ-
NOH, 6-methoxy-8-hydroxylaminoquinoline; 6-DesM-PQ, 6-desmethylprimaquine; 5-
HPQ, 5-hydroxyprimaquine; 6-MAQ, 6-methoxy-8-aminoquinoline; 5-0H-6-MAQ, 5-
hydroxy-6-methoxy-8-aminoquinoline; 5,6-DHAQ, 5,6-dihydroxy-8-aminoquinoline; 
5,6-DHPQ, 5,6-dihydroxyprimaquine. 
(Bolchoz et al., 200 1) 
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5-Hydroxyprimaquine 
Following the suggestions of Tarlov et a!. (Tarlov et a!., 1962), much attention has 
been given to the putative phenolic metabolites of primaquine (5-HPQ, 5,6-DHPQ, 5-
OH-6-MAQ, and 5,6-DHAQ), which are thought to support quinone- or quinoneimine-
type redox-cycling and generation ofROS as shown in Fig. 1.10 (Link et a!., 1985). To 
examine the hemotoxic potential of these putative metabolites, several of the phenolic 
metabolites were synthesized in the 1980s and made available to investigators under a 
contract funded by the WHO. Studies with these derivatives in isolated erythrocytes 
showed that they were able to oxidize hemoglobin, stimulate hexose monophosphate 
shunt activity and deplete erythrocytic GSH (Allahyari et a!., 1984; Link et aI., 1985; 
Agarwal et a!., 1988; Fletcher et a!., 1988). Additionally, more recent studies from our 
laboratory assessed the hemotoxicity of MAQ-NOH, a hydroxylamine-type metabolite, 
which was shown to be directly hemotoxic to red cells (Bolchoz et a!., 2001). 
Collectively, these studies have led our laboratory to propose that the complex 
metabolism of primaquine can be simplified into three types of reactive metabolites: N-
nitroso, p-quinoneimine-, and o-quinone-type metabolites (Fig. 1.10). While the 
quantitati ve importance of each of these metabolites is not yet known, each type is 
thought to have the ability to redox cycle and thereby generate reactive oxygen species 
according to the scheme shown in Fig. 1.11. While the initial experiments effectively 
demonstrated the oxidative activity of phenolic metabolites in vitro, they failed to 
establish a relevant model to assess whether their activities in vitro were relevant to the 
hemotoxicity observed in vivo. Thus, little is known about the capacity of phenolic 












Fig. 1.10. Structures of types of primaquine reactive metabolite redox pairs. R=alkyl 















Fig. 1.11. Working hypothesis for quinoneimine-induced oxidative stress in red cells. 5-HPQ = 
5-hydroxyprimaquine;QI = 5-hydroxyprimaquine-quinoneimine; Hb++ = ferrohemoglobin; 




primaquine-treated humans have not been successful. Furthermore, the compounds 
initially offered by the WHO are no longer available, are difficult to synthesize, and are 
extremely unstable. 
5-HPQ, which is formed by hydroxylation in the 5-position of the quinoline ring, is 
the most simple of the putative phenolic metabolites. Although it has not been found in 
humans, formation of 5-HPQ from primaquine is expected, since it would arise by a 
single metabolic step and has been shown to be formed in several experimental animals, 
including rats, dogs and monkeys (Strother et aI., 1981; Fletcher et aI., 1984; Ni et aI., 
1992). Additional studies have shown that 5-HPQ can generate H20 2 and hydroxyl 
radicals within the red cell. It was suggested that this formation of ROS was the result of 
an iron-catalyzed reaction between the semiquinone intermediate and H20 2 (Vasquez-
Vivar and Augusto, 1992). It is conceivable that this generation of intracellular ROS 
could mediate the hemolytic damage of primaquine in G6PD-deficient individuals, who 
are unable to sufficiently replenish GSH. 
Similar to the other phenolic metabolites mentioned above, 5-HPQ has been shown 
to deplete glutathione, form methemoglobin, and stimulate HMP-shunt activity. 
However, there is no evidence that 5-HPQ has a direct hemolytic effect, and it is not 
known whether the conditions under which 5-HPQ was shown to cause oxidative 
damage in vitro are relevant to those that cause hemolytic damage in vivo. 
Rationale and Specific Aims. 
The mechanism underlying primaquine-induced hemolytic injury is unknown. 
Current thinking is that primaquine itself is not responsible, but rather cellular injury 
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results from an oxidative stress generated within the red cell by redox-active metabolites. 
A classical approach to identify the toxic metabolites (Le. administration of primaquine in 
vivo in order to match toxicity to the formation of a metabolite) cannot be used, because 
rats (and humans with normal G6PD activity) do not respond to primaquine with toxicity, 
as noted above. In addition, the reactivity of certain metabolites in blood, i.e. 5-HPQ, 
does not allow for the correlation of blood levels with toxicity. Thus an alternative 
approach must be used. 
Three types of redox-active metabolites are known or postulated to arise during the 
hepatic metabolism of primaquine: an N-hydroxy derivative (MAQ-NOH); and two 
phenolic derivatives, 5-HPQ and 5-hydroxy-6-desmethyl primaquine. Previous studies in 
our lab focused on MAQ-NOH, a hydroxylamine-type metabolite. MAQ-NOH was 
shown to be a direct-acting hemolytic agent in rats and to have the requisite properties to 
contribute to the overall hemotoxicity of primaquine (Bolchoz et al., 2001). The 
following studies are focused on the more simple of the two putative phenolic 
metabolites, 5-HPQ, since it would arise by a single metabolic step and hence may be 
formed in larger amounts. Previous studies showed that 5-HPQ could redox cycle to its 
quinoneimine analog, generate methemoglobin and cause loss of GSH when added to red 
cells in vitro (Allahyari et aI., 1984; Link et aI., 1985; Agarwal et ai., 1988; Fletcher et 
ai., 1988). Thus, 5-HPQ appears to be an redox-active metabolite that might be able to 
mediate the overall hemotoxicity of primaquine. 
The long-term objective of these studies is to design a "better primaquine"; that is, a 
derivative that retains antimalarial activity but has little or no hemolytic capacity. Our 
fundamental contention is that an improved drug can only be developed if the mechanism 
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of toxicity is understood. To this end, the present studies will seek to establish: 1) the 
direct hemolytic activity of 5-HPQ; 2) the nature of injury induced within the red cell by 
5-HPQ, and 3) the relationship between these internal oxidative changes with the 
premature sequestration of 5-HPQ-damaged red cells. The information obtained should 
be useful in modulating metabolism and/or RBC in the rat to confer "primaquine 
sensitivity" and to examine the pattern of oxidative damage in order to determine which 
type(s) of metabolites contribute. These studies will also significantly advance our 
understanding of the general mechanism of drug-induced hemolytic anemia, i.e. 
examination of the nature of the cellular oxidative damage will allow us to assess the 
relevance of specific lesions to the premature removal of damage cells, which could also 
provide insight into the normal, physiologic removal of senescent erythrocytes. 
Hypothesis: 5-HPQ causes the hemolytic removal of damaged erythrocytes in rats by 
initiating an intracellular oxidative stress that specifically alters membrane components 
and leads to recognition and uptake of intact cells by splenic macrophages. 
Specific Aim 1. To characterize the chemical properties, hemolytic response and pattern 
of oxidative injury induced in rat erythrocytes by 5-HPQ. 
Specific Aim 2. To determine the role of splenic macrophages in the fate of 5-HPQ-
damaged rat erythrocytes. 
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Specific Aim 3. To examine the role of membrane lipid peroxidation and cytoskeletal 
protein alterations in the hemotoxicity of 5-hydroxyprimaquine. 
CHAPTER 2 
Primaquine-Induced Hemolytic Anemia: Susceptibility of Normal 
versus GSH-Depleted Rat Erythrocytes to 5-Hydroxyprimaquine 
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Introduction 
Malaria is a widespread, life-threatening parasitic disease that is responsible for 300-
500 million acute illnesses and an estimated 1.5-2.7 million deaths worldwide each year 
(Kain and Keystone, 1998). Primaquine, an 8-aminoquinoline anti-malarial drug, is 
effective against the exoerythrocytic forms of all four of the malarial species that infect 
humans and is the only radically curative drug for the latent tissue forms of Plasmodium 
vivax and P. ovale (Tracy and Webster, 2001). Primaquine is also used in combination 
with chloroquine to combat the problem of multiple drug resistance in P. Jalciparum 
(Shanks et aI., 2001). Despite its clinical importance and effectiveness, use of primaquine 
has long been known to be limited by its capacity to induce hemolytic anemia, 
particularly in individuals with a hereditary deficiency in erythrocytic glucose-6-
phosphate dehydrogenase (G6PD) activity (Dern et aI., 1955; Degowin et aI., 1966). 
Since G6PD deficiency is prevalent in malarial areas, this dose-limiting toxicity can have 
a major impact on the usefulness of this drug in these populations. 
Importantly, primaquine is not directly toxic to erythrocytes at clinically relevant 
concentrations. Although the hemotoxicity of primaquine has long been considered to be 
dependent on metabolism, the metabolite(s) responsible and the underlying mechanism(s) 
have remained unclear. We have reported recently that 6-methoxy-8-
hydroxylaminoquinoline (MAQ-NOH), an N-hydroxylated metabolite of primaquine, is a 
direct-acting hemolytic and methemoglobinemic agent in rats, and therefore may be a 
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contributor to the hemotoxicity observed in primaquine-treated humans (Bolchoz et aI., 
2001). 
Metabolism of primaquine, however, is relatively complex, and a variety of known 
and putative phenolic metabolites have also been considered to be capable of mediating 
primaquine hemotoxicity. In particular, hydroxylation of primaquine at the 5-position of 
the quinoline ring (Fig. 2.1) is known to yield redox active derivatives that are capable of 
inducing oxidative stress within normal and G6PD-deficient human erythrocytes. Several 
of these compounds, including 5-hydroxyprimaquine (5-HPQ), 5-hydroxy-6-
desmethylprimaquine and their N-dealkylated derivatives, were synthesized in the 1980s 
and made available to investigators by the World Health Organization. Studies with these 
compounds in isolated suspensions of red cells have shown that they can induce 
methemoglobin formation, glutathione (GSH) depletion and stimulation of hexose 
monophosphate shunt activity (Allahyari et aI., 1984; Link et aI., 1985; Baird et aI., 1986; 
Agarwal et aI., 1988; Fletcher et aI., 1988; Vasquez-Vivar and Augusto, 1994). However, 
there is a notable lack of evidence for their hemolytic activity in vivo. 
Progress towards understanding the role of phenolic metabolites in primaquine-
induced hemolytic anemia has been hampered because they are no longer available, the 
synthetic methods to prepare them are relatively difficult, and the products are highly 
unstable. As a first step in our investigation of the potential contribution of phenolic 
metabolites to primaquine-induced hemolytic anemia, we have re-synthesized 5-HPQ and 
examined its stability and redox behavior. In addition, we have assessed the hemolytic 
potential of 5-HPQ in aSH-normal and GSH-depleted rat red cells. In view of the critical 






Fig. 2.1. Putative metabolism of primaquine to 5-HPQ. 
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hemolytic anemia, we measured the formation of methemoglobin and monitored red cell 
sulfhydryl status under hemolytic conditions in order to correlate the hemolytic response 
with these indicators of intracellular oxidative damage. We report that 5-HPQ is an 
extremely potent direct-acting hemolytic agent in rats, and that hemolytic activity is 
associated with methemoglobin formation and a marked depletion of erythrocytic GSH. 
When GSH was depleted from rat red cells to mimic aSH instability of human G6PD-
deficient red cells (Gaetani et aI., 1979), the hemolytic activity of 5-HPQ was markedly 
enhanced. The significance of the data with regard to the overall contribution of 
metabolites to primaquine-induced hemolytic anemia is discussed. 
Materials and Methods 
Chemicals and Materials. 
6-Methoxy-8-nitroquinoline, ferrous bromide, sodium metal, stannous chloride, 
potassium trifluoroacetate and GSH were obtained from Sigma-Aldrich (St. Louis, MO). 
Na2
51Cr04 in sterile saline (1 mCi/ml, pH 8) was obtained from New England Nuclear 
(Billerica, MA). All other chemicals and reagents were of the best grade commercially 
available. 
5 -Methoxyprimaquine (5, 6-dimethoxy -8-[4-amina-l-methy lbuty lamina ]quinoline) 
was pre-pared from 6-methoxy-8-nitroquinoline as described previously and shown in 
Fig. 2.2 (Elderfield et aI., 1955). 5-HPQ (5-hydroxy-6-methoxy-8-[4-amino-l-methyl-
but ylamino] quinoline) was synthesized from 5-methoxyprimaquine by HBr-catalyzed 
hydrolysis using a modification of an established method (Allahyari et aI., 1984). The 
composition of the reaction mixture was monitored as a function of time via LC-MS. The 
Br2F e, CaC03 .. 


























Fig. 2.2. Schematic representation of the synthesis of 5-HPQ. 6-methoxy-8-
nitroquinoline (1) was brominated by electrophilic substitution to form 5-bromo-6-
methoxy-8-nitroquinoline (2). Nucleophilic aromatic substitution of 2 with sodium 
methoxide produced 5,6-dimethoxy-8-nitroquinoline (3), which was then reduced with 
tin(II) chloride to form 5,6-dimethoxy-8-aminoquinoline (4). 4-bromo-l-phthalimido-
pentane (5) was used to alkylate 4 to form 5,6-dimethoxy-8-(4-phthalimido-l-methyl-
butylamino)-quinoline (6). Hydrazinolysis of 6 formed 5-methoxyprimaquine (7), which 
yielded 5-HPQ (8) and a mixture of products (9,10) after selective hydrolysis with HBr. 
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reaction mixture contained four major components (Fig. 2.3): 5-HPQ (m1z 275.5-276.5; 
4.60 min, 21.0%), 5-HPQ quinoneimine (273.5-274.5; 4.41 min, 42.8%), 5-
methoxyprimaquine (m/z 289.5-290.5; 9.58 min, 21.1%) and 5-hydroxy-6-
desmethylprimaquine (mlz 259.5-260.5; 4.09 min, 15.1 %). The yield of 5-HPQ was 
optimized by adjusting the reaction temperature to 120° C and the reaction time to 20 
min. The yield was increased further by reducing the quinoneimine to the hydroquinone 
using sodium dithionite and maintaining the reaction mixture under argon to minimize 
oxidation of the hydroquinone. The reaction mixture was then purified in two steps using 
SepPak Plus C18 cartridges (Waters Corporation, Milford, MA). 5-HPQ was eluted from 
the first cartridge with 5% acetonitrile/0.05% aqueous trifluoroacetic acid, lyophilized 
and then applied to a second cartridge. 5-HPQ was eluted from the second cartridge with 
5% acetonitrile in water containing 5 mM HBr. After removal of the solvent by 
lyophilization, elemental analysis confirmed the presence of the trihydrobromide salt of 
5-HPQ (purity >99% as judged by HPLC and NMR analysis). IH NMR (in D20; Fig. 
2.4): [) 8.62 (dd, 1=1.4, 4.4 Hz, 1, H-2), 8.43 (dd, J=8.5, 1.4 Hz, 1, H-4), 7.46 (s, 1, H-7), 
4.40 (dd, 4.3, 8.5 Hz, 1, H-3), 3.76 (m, 2, H-l '), 3.82 (s, 3, OCH3), 2.77 (m, 2, H-4'), 
1.65 (m, 1, H-2'), 1.65 (m, 1, H=3'), 1.56 (m, 1, H-2'), 1.52 (m, 1, H-3'), 1.19 (d, J=6.6 
Hz, 3, H-5'). 13C NMR (in D20): [) 148.6 (C-2), 142.7 (C-6), 139.7 (C-5), 134.9 (C-9), 
132.4 (C-4), 122.4 (C-8), 121.8 (C-3), 120.4 (C-I0), 112.8 (C-7), 57.9 (C-l '), 57.6 
(OCH3), 38.9(C-4'), 29.7 (C-2'), 23.1 (C-3'), 15.9 (C-5'). Because 5-HPQ is unstable, 
even when stored in the dark under argon at -80°C, it was routinely prepared for 
immediate use (i.e., within 24-48 hr) from its more stable precursor, 5-
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Fig. 2.3. LC-MS analysis of key reaction products from the selective hydrolysis of 5-methoxyprimaquine. ~ 0-.. 
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HPLC Analysis. 
Chromatography was performed on a Waters HPLC system (Milford, MA) consisting 
of a model 510 pump, a Rheodyne injector (5-mlloop), and a 250-mm Alltech Platinum 
EPS C18 reverse phase column. 5-HPQ was eluted with 10% acetonitrile in water 
containing 0.05% trifluoroacetic acid at a flow rate of 1.1 ml/min, and was detected on a 
Waters model 481 UV -Vis variable wavelength detector set at 254 nm. For stability 
studies, a Bioanalytical Systems H-PLC system (West Lafayette, IN) consisting of a 
model PM-80 pump, a Rheodyne 7125 injector (20 JlI loop), and a 150-mm Alltech 
Platinum EPS CI8 reverse phase column was used. 5-HPQ was eluted with 7% 
acetonitrile in water containing 0.05% trifluoroacetic acid and 50 mM potassium 
trifluoroacetate at a flow rate of 1.0 ml/min, and was detected using a Bioanalytical 
Systems Epsilon electrochemical detector equipped with a glassy carbon working 
electrode (oxidation mode, +0.35 V) and a Ag/AgCI reference electrode. 
NMR Spectroscopy and Mass Spectrometry. 
Proton and carbon NMR spectra were obtained on a Varian Inova spectrometer 
operating at 400 and 100 MHz, respectively_ Proton assignments were made by employing 
the double quantum filtered COSY experiment acquired in the phase sensitive mode. 2x256 
fids were acquired. Digital resolution in FI was increased by linear prediction to 1024 
points, processed using the Gaussian weighting function, then Fourier transformed. The 
chemical shifts of unresolved multiplets were based on the chemical shifts of the cross 
peaks. Carbon resonances were assigned using gradient versions of the heteronuclear single 
quantum coherence (HSQC) and heteronuclear multi-bond correlation (gHMBC) 
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experiments. In the HSQC 128 fids were acquired. Linear prediction increased the points in 
Fl to 512, Gaussian weighted, then Fourier transformed. In the HMBC 400 fids were 
acquired, linear prediction increased the points in Fl to 1200, sinebell weighted, then 
Fourier transformed. The nuclear Overhauser effect spectroscopy (NOESY) experiment 
was acquired in the phase sensitive mode by collecting 2x256 fids. Digital resolution in Fl 
was increased by linear prediction to 1024 points, processed using the Gaussian weighting 
function, then Fourier transformed. Presence of a methoxy group in the 6-position of 5-
HPQ was verified by the NOESY experiment. 
Mass spectra were obtained using a Finnigan LCQ ion trap mass spectrometer 
(Thermo-Finnigan Instrument Systems Inc., San Jose, CA). A 150-mm Alltech Platinum 
EPS C18 reverse phase column was used. The sample was eluted with 10% acetonitrile in 
water containing 0.05% trifluoroacetic acid at a flow rate of 0.5 mllmin. The column 
effluent was split and 10% was directed to the ESI source. Instrument parameters were as 
follows: ESI needle voltage, 4.5 kV; ESI capillary temperature, 200°C; ion energy, 45%; 
isolation window, 1 amu; scan range, 150.0-1000.0 amu. MS and MS/MS data were 
acquired automatically using Xcalibur software (version 1.2). 
Electrochemical Activity of 5-HPQ. 
Cyclic voltammetry was performed using a Bioanalytical Systems (West Lafayette, 
IN) CV-27 voltammograph, C-IA/B cell stand, and a Model RXY recorder. Stock 
solutions of 5-HPQ (245 ~M) were prepared in argon-purged isotonic phosphate-buffered 
saline (pH 7.4) supplemented with 10 mM D-glucose (PBSG). Samples were scanned at a 
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rate of 150 mV/s at room temperature under an argon atmosphere using a carbon-paste 
working electrode, a platinum auxiliary electrode and an AgI AgCI reference electrode. 
Animals and Erythrocyte Incubation Conditions. 
Male Sprague-Dawley rats (75-100 g) were purchased from Harlan Laboratories 
(Indianapolis, IN), and maintained on food and water ad libitum. Animals were 
acclimated for 1 week to a 12-h light-dark cycle prior to their use. Blood from the 
descending aorta of anesthetized rats was collected into heparinized tubes and washed 
three times with PBSG to remove the plasma and buffy coat. The cells were resuspended 
to a 40% hematocrit in PBSG and used the same day they were collected. Stock solutions 
of 5-HPQ in argon-purged water were prepared to deliver the appropriate concentration 
of 5-HPQ in 10 JlI to erythrocyte suspensions (1-3 ml). 
Measurement of Hemolytic Activity. 
The survival of rat s1Cr-Iabeled red cells was determined in vivo after in vitro 
incubation with various concentrations of 5-HPQ (25-300 JlM). After incubation for 2 hr 
at 37°C, the erythrocytes were washed once and resuspended in PBSG (40% hematocrit). 
Aliquots (0.5 ml) were administered intravenously to isologous rats. To blood samples 
were taken from the orbital sinus 30 min after administration of labeled red cells. 
Additional blood samples were taken every 48 hr for 14 days. At the end of the 
experiment, the samples were counted in a well-type gamma counter, and the data were 
expressed as a percentage of the To blood sample. The hemolytic response was quantified 
by calculating the fraction of radiolabeled red cells that were removed from the 
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circulation within the first 48 hr for each animal by linear regression as described 
previously (McMillan et aI., 2001). Statistical significance was determined with the use 
of Student's t test. 
Determination of Methemoglobin Formation and Sulfhydryl Status. 
Methemoglobin levels in erythrocyte suspensions treated with 5-HPQ (25-1000 ~M) 
were measured using a modification of the spectrophotometric technique of Evelyn and 
Malloy (Evelyn and Malloy, 1938) as described previously (Harrison and Jollow, 1987). 
For determination of sulfhydryl status, aliquots (200 f..tl) of the erythrocyte 
suspensions were removed at various intervals after addition of 5-HPQ and assayed for 
GSH, oxidized glutathione (GSSG), and glutathione-protein mixed disulfides (PSSG) by 
HPLC with electrochemical detection as described previously (Grossman et aI., 1992). 
The amount of sulfhydryl present in the samples was determined by comparison of peak 
areas to prepared standards. 
GSH Depletion of Erythrocyte Suspensions. 
Diethyl maleate (DEM) was used to deplete GSH in red cell suspensIons as 
previously described (Bolchoz et aI., 2002b). Briefly, DEM (750 f..tM) dissolved in 
acetone was added to packed red cells. Following a 15-minute incubation at 37°C, the red 
cells were analyzed for aSH content by HPLC with electrochemical detection as 
described above. Under these conditions, GSH was reduced to about 5% of initial levels. 
The cells were resuspended to a 40% suspension in PBSa and used on the same day that 
they were collected. 
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Results 
Stability and Electrochemistry of 5-HPQ. 
NMR studies undertaken as part of the characterization of the newly synthesized 5-
HPQ indicated that it was stable for over 24 hr when maintained at low pH under strictly 
anaerobic conditions. This indicated that it could be prepared and kept as a solution 
without significant degradation before its experimental use in erythrocyte suspensions. 
On the other hand, previous work had shown 5-HPQ to be unstable in the presence of 
oxygen (at pH 8.5) due to its facile conversion to its quinoneimine form (Vasquez-Vivar 
and Augusto, 1990). 
Therefore, to determine the stability of the 5-HPQ hydroquinone/quinoneimine redox 
pair under our experimental conditions, 5-HPQ (500 JlM) was added to aerobic PBSG 
(pH 7.4) in the absence and presence of red cells. Aliquots were withdrawn at intervals, 
treated with an excess of sodium dithionite, and then assayed for 5-HPQ by HPLC-EC 
(Fig. 2.5). Rapid loss of 5-HPQ occurred in both situations with a half-life of about 45 
sec in the absence of red cells and about 30 sec in their presence. Since the hydroquinone 
and quinoneimine forms of 5-HPQ were not well separated on the HPLC-EC column, 
LC-MS analysis (in which both halves of the redox pair could be detected independently 
by selected ion monitoring) confirmed that the disappearance of 5-HPQ was not due 
simply to its oxidation to the quinoneimine during chromatographic analysis, but instead 
was due to the complete degradation of the redox pair (data not shown). 
Previous studies have shown that in the presence of an excess of NADPH and a 
catalyst (ferredoxin:NADP+ oxidoreductase), 5-HPQ can generate greater than 














o 0.5 1 1.5 2 2.5 
Time (min) 
53 
Fig. 2.5. Stability of 5-HPQ in blood versus buffer. 5-HPQ (500jlM) was added to 
buffered saline in the absence and presence of erythrocytes (40% hematocrit) and allowed 
to incubate aerobically at 37°C. Aliquots were removed at designated intervals, treated 
with dithionite, and assayed for 5-HPQ concentration using HPLC with electrochemical 
detection. Values are expressed as a percentage of the concentration at To and are means 
± S.D. (n = 3). 
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suggests that this compound has the ability to redox cycle. To determine directly whether 
oxidation of 5-HPQ to its quinoneimine form is reversible, we examined its 
electrochemical activity in argon-purged PBSG (pH 7.4) using cyclic voltammetry. As 
shown in Fig. 2.6, when an excitation potential scan was initiated in the positive 
direction, two oxidation products (peaks A and B) were observed. When the potential 
scan was reversed (in the negative direction), a reduction product (peak C) was observed. 
These data are consistent with a concerted oxidation of 5-HPQ hydroquinone to 5-HPQ 
quinoneimine (peak B) via a semiquinone radical intermediate (peak A), as suggested by 
previous work (Vasquez-Vivar and Augusto, 1992). Peak C corresponds to the reduction 
of the oxidized products formed on the forward scan back to 5-HPQ hydroquinone. These 
electrochemical data support the concept that 5-HPQ can undergo cycling as a fully 
reversible redox couple at physiological pH. 
Direct Hemolytic Activity of 5-HPQ. 
Although a variety of studies on the oxidative activity of 5-HPQ in red cells have 
been published, its direct hemolytic activity has not been established. To investigate the 
hemolytic potential of 5-HPQ, rat sler-Iabeled erythrocytes were incubated with various 
concentrations of 5-HPQ for 2 h at 37°C. The cells were then washed and returned to the 
circulation of isologous rats. A To blood sample was taken from the orbital sinus 30 min 
after administration of the labeled red cells, and then serial blood samples were taken at 
48 hr intervals for 14 days. As shown in Fig. 2.7 A, exposure of the labeled cells to 5-
HPQ caused a concentration-dependent increase in the rate of removal of radioactivity 










Fig.2.6. Cyclic voltammogram of 5-HPQ (245 f.lM) in argon-purged PBSG (pH 7.4) at room 
temperature. Working electrode, carbon paste; reference electrode, Ag/ AgCl; auxiliary 
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Fig. 2.7. A, survival of rat 51Cr-Iabeled erythrocytes in vivo after in vitro exposure to 5-
HPQ. Radiolabeled erythrocytes were incubated for 2 hr at 37°C with the indicated 
concentrations of 5-HPQ; control cells were incubated with vehicle (10 f..tl H20). The 
erythrocytes were then washed and re-administered intravenously to isologous rats. To 
blood samples were taken 30 min after administration of labeled cells. Data points are 
means ± S.D. (n=4). B, concentration dependence for the hemolytic response following 
5-HPQ exposure. Values are means ± S.D. (n=4). 
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response curve for the hemolytic activity of 5-HPQ. The concentration-response curve for 
5-HPQ was extremely sharp, with an apparent threshold concentration of about 25 J..lM, a 
TC50 of approximately 40 t-tM, and a maximal response at about 100 t-tM. 
Methemoglobin Formation by 5-HPQ. 
5-HPQ has been previously shown to deplete red cell GSH and induce 
methemoglobin formation (Allahyari et aI., 1984; Link et aI., 1985; Baird et aI., 1986; 
Agarwal et aI., 1988; Fletcher et aI., 1988; Vasquez-Vivar and Augusto, 1994). To 
determine the relationship between these endpoints and the hemolytic response, we 
examined the time- and concentration-dependence of methemoglobin formation in rat 
erythrocyte suspensions exposed to 5-HPQ. As shown in Fig. 2.8A, incubation of a rat 
red cell suspension with a maximal hemolytic concentration of 5-HPQ (100 t-tM) resulted 
in the rapid formation of methemoglobin. This concentration produced peak 
methemoglobin level of only about 20%, which nevertheless remained constant over the 
2 hr incubation period. Fig. 2.8B depicts the concentration dependence of the 
methemoglobinemic response to 5-HPQ at 30 min post-exposure. Methemoglobin levels 
ranged from approximately 3.5% at 25 t-tM 5-HPQ to a maximum of about 40% at 300 
t-tM (TC50 ca. 100 t-tM). 
Effect of 5-HPQ on Rat Erythrocyte Sulfhydryl Status. 
To examine the fate of red cell GSH following treatment with hemolytic 
concentrations of 5-HPQ, aliquots were taken at various intervals and analyzed for GSH, 
GSSG, and PSSG levels by HPLC-EC. As shown in Fig. 2.9A, addition of 100 ~M 5-
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Fig. 2.8. Effect of 5-HPQ on methemoglobin formation in rat erythrocytes. A, rat 
erythrocytes were treated with 5-HPQ (100 j.lM) and assayed for methemoglobin levels over 
time; control cells were incubated with vehicle (10 j.ll H20). Data points are means ± S.D. 
(n=3). B, concentration-dependence for methemoglobin formation. Aliquots of the incubation 
mixture were assayed for methemoglobin 30 min after exposure to 5-HPQ (25-1000 j.lM). 
Data points are means ± S.D. (n=3). 
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HPQ to rat red cells resulted in a complete depletion of GSH within 15 min. The loss of 
GSH was matched by an increase in PSSG; GSSG remained low throughout the 
incubation period. The concentration dependence of the 5-HPQ-induced depletion of 
GSH is shown in Fig. 2.9B. As with the hemolytic response (Fig. 2.7B), a sharp 
concentration response curve was observed, with a TC50 of approximately 40 J.1M. 
Hemolytic Activity of 5-HPQ in GSH-Depleted Erythrocytes. 
The enhanced susceptibility displayed by G6PD-deficient individuals to primaquine-
induced hemolytic anemia is thought to be due to an inability to maintain sufficient levels 
of NADPH, and thus reduced glutathione, in response to the oxidative stress. To 
reproduce in rat erythrocytes the instability of GSH known to occur in human G6PD-
deficient erythrocytes, 51Cr-Iabeled red cells were titrated with DEM to deplete GSH by 
>95%. The aSH-depleted red cells were then exposed to various concentrations of 5-
HPQ in vitro for 2 hr at 37°C, and their survival was determined in vivo. As shown in Fig. 
2.10A, the survival of untreated GSH -depleted red cells (T 50 = 11.0 ± 1.9 days) was not 
significantly different from the survival of GSH-normal red cells (Fig. 4A; T50 = 9.8 ± 0.8 
days). As expected from the previous experiment, the rate of removal of GSH-normal red 
cells exposed to a sub-hemolytic concentration of 5-HPQ (10 J.1M) was also not 
significantly different from the controls (Fig. 2.10A). In contrast, exposure of GSH-
depleted red cells to a 10 J.1M concentration of 5-HPQ provoked a dramatic increase in 
their rate of removal. Quantitation of the hemolytic response for GSH-depleted red cells 
(Fig. 2.10B) revealed the concentration-response curve to be shifted significantly to the 
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Fig. 2. 9. Effect of 5-HPQ on rat erythrocyte sulfbydryl status. A, rat red cells were 
incubated at 37°C in PBSG containing 5-HPQ (100 ~M). At the indicated time points, 
aliquots were withdrawn and assayed for GSH, GSSG, and glutathione-protein mixed 
disulfides (PSSG). Data points are means ± S.D. (n=3). B, concentration dependence for 
GSH depletion by 5-HPQ (5-100 ~M) in rat erythrocytes. GSH concentration was 
determined before addition of 5-HPQ and again at 15 min post-exposure. Values are 
expressed as a percentage of the initial level and are means ± S.D. (n=3). 
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left of the response curve for aSH-normal cells (Fig. 2.7B), with a TCso under these 
conditions of about 7.5 f.lM. 
Discussion 
Oxidative metabolism has long been known to playa critical role in the onset of 
primaquine-induced hemotoxicity, and phenolic metabolites have been considered the 
most likely candidates for mediating both the hemolytic and methemoglobinemic 
responses that have been observed during the course of therapy with this antimalarial 
drug. Considerable attention has been given to the 5-hydroxy- and 5,6-dihydroxy 
metabolites of primaquine because they have the potential to redox cycle (via 
quinoneimine and 5,6-quinone formation, respectively) and generate reactive oxygen 
species. Support for the importance of phenolic metabolites has come from a variety of in 
vitro studies which showed that these compounds were able to induce oxidative changes 
within red cells, such as stimulation of hexose monophosphate shunt activity, GSH 
depletion and hemoglobin oxidation. What has been missing from these efforts, however, 
is evidence that links these biochemical changes observed in vitro to loss of erythrocyte 
viabili ty in vivo. 
The present results demonstrate that a redox active phenolic metabolite of 
primaquine, 5-HPQ, is a direct-acting hemolytic agent in the rat (Fig. 2.7). This loss of 
erythrocyte viability in vivo was correlated with a rapid and extensive depletion of GSH 
(Fig. 2.9A), which exhibited a concentration dependence that coincided with that of the 
hemolytic response (Fig. 2.9B). The disappearance of GSH was matched by the 
62 
A B 
100 • Control 100 
• 10 J.lM 
-0 90 0 Cant -GSJ:i 90 
0 ....--. 
0 80 l::i. 5 J.lM -GSH ~ 80 0 
CO 
......,. 
0 10 J,tM -GSH Q) c::: 70 0> 70 
0> 
~ 
c::: 60 E 60 
c::: ~ 
~ 50 Cl 50 
E (,) 
Q) 40 ~ 40 
a: 0 
~ 30 E 30 0 Q) 




0 2 4 6 8 10 12 14 0.1 1 10 100 
Time (days) 5-HPQ (f.tM) 
Fig. 2.10. A, survival of normal vs. GSH-depleted rat 51Cr-Iabeled erythrocytes in vivo 
after in vitro exposure to 5-HPQ. Radiolabeled red cells were treated with DEM to 
deplete intracellular GSH (>95%). The cells were incubated for 2 hr at 37°C with the 
indicated concentrations of 5-HPQ; GSH-depleted control cells were incubated with 
vehicle (10 f.!1 H20). Data points are means ± S.D. (n=4). B, concentration-dependence 
for the hemolytic response in GSH-depleted red cells. Values are means ±S.D. (n=3). 
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formation of mixed disulfides between GSH and the soluble protein of the red cell. The 
importance of GSH status in determining the sensitivity of rat red cells to this hemolytic 
agent is illustrated by the data in Fig. 2.10A, which shows that depletion of GSH with 
DEM prior to 5-HPQ exposure caused a marked enhancement of the hemolytic response. 
These data strongly support the concept that the hemolytic response has a discrete dose 
threshold and that this threshold is dependent on the presence GSH in the red cell. 
Although the in vitro exposure/in vivo survival data presented in Fig. 2.7 do not allow 
for a direct assessment of the role of 5-HPQ in primaquine hemotoxicity, this assay does 
permit the hemolytic damage observed in vivo to be reproduced in vitro under controlled 
conditions during a 2-hr incubation period before the red cells are returned to the 
circulation of rats, and thus serves as a useful indicator of the relative potency among 
direct-acting hemolytic agents. Interestingly, 5-HPQ is the most potent hemolytic agent 
we have examined to date. The TCso of 5-HPQ (ca. 40 f.tM) was about 3.5-fold lower than 
that of dapsone hydroxylamine (TCso ca. 150 f.tM), an N-hydroxy metabolite known to be 
the sole mediator of the hemolytic activity of dapsone, and about 8.5-fold lower than that 
of MAQ-NOH (TCso ca. 350 f.tM), an N-hydroxy metabolite shown recently by our 
laboratory to have the requisite properties to mediate primaquine hemotoxicity. Of 
interest, the potency of 5-HPQ was increased by more than 5-fold in GSH-depleted red 
cells (TCso ca. 7.5 f.tM). 
As shown in Fig. 2.8A, hemolytic concentrations of 5-HPQ were associated with the 
formation of methemoglobin, however, the concentration response curve for 
methemoglobin formation (Fig. 2.8B) was shifted well to the right of the hemolytic 
concentration response curve. In addition, the methemoglobinemic efficacy of 5-HPQ 
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was limited to about 40% of the maximum response, even when extremely high (1 mM) 
concentrations were used. Although the reason for this lack of efficacy and low relative 
potency is unknown and requires further investigation, it may be related to the marked 
instability of 5-HPQ in the presence of red cells (Fig. 2.5). Alternatively, 5-HPQ may 
interfere with the normal reduction of methemoglobin, either by depletion of reducing 
cofactors (NADH/NADPH) andlor inhibition of cellular reductases, or by generating 
more stable oxidants that continue to generate methemoglobin at a rate that exceeds its 
reduction. In any case, the concentration response data suggest that the mechanisms 
underlying methemoglobin formation and hemolytic activity of 5-HPQ may be unrelated. 
Taken together, these data strongly support a role for 5-HPQ in primaquine-induced 
hemolytic anemia, and furthermore, may provide an explanation for the dramatic 
difference in primaquine sensitivity between G6PD-deficient and G6PD-normal 
individuals. Data published by Degowin et al. (1966) showed that doses of primaquine 
necessary to provoke a hemolytic response in G6PD-deficient humans are about 20-fold 
lower than those required to elicit a similar response in G6PD-normal individuals, 
whereas the doses of dapsone required to induce similar responses in G6PD-deficient vs. 
normal differed by only a factor of 2. Although the reason for the difference in 
susceptibility between dapsone and primaquine is not yet understood, it may be related to 
the fact that dapsone hemotoxicity is mediated by a single hydroxylamine metabolite, 
whereas primaquine hemotoxicity may be mediated by the synergistic action of multiple 
toxic metabolites, including N-hydroxy, quinoneimine and quinone . . 
In summary, we have demonstrated that a phenolic metabolite of primaquine, 5 .. HPQ, 
is directly hemotoxic to the rat red cell. We have also shown that the hemotoxicity is 
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highly dependent on the level of GSH in the red cell, which suggests that GSH status may 
underlie the apparent threshold for primaquine hemotoxicity in G6PD deficiency. The 
actual contribution of this metabolite, however, to primaquine hemotoxicity remains to be 
assessed. 
CHAPTER 3 
Primaquine-Induced Hemolytic Anemia: 
Role of Splenic Macrophages in the Fate of 
5-Hydroxyprimaquine-Treated Rat Erythrocytes 
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Introduction 
The hemolytic anemia induced by the antimalarial drug, primaquine, has long been 
known to be due to an accelerated uptake of oxidatively damaged erythrocytes into the 
spleen (Beutler, 1969). Individuals who have a deficiency in erythrocytic glucose-6-
phosphate dehydrogenase (G6PD) activity have an enhanced susceptibility to primaquine 
because they are unable to generate sufficient NADPH, and hence reduced GSH, to 
detoxify reactive oxygen species (ROS) generated by the drug. It is also well accepted 
that primaquine itself is not biologically active in erythrocytes at toxicologically relevant 
concentrations, but that redox active metabolites, produced by CYP-catalyzed ring- and 
N-hydroxylation, are responsible for the hemolytic injury that occurs after administration 
of the parent compound. 
One of the ring-hydroxylated metabolites, 5-hydroxyprimaquine (5-HPQ), has long 
been postulated to be capable of mediating primaquine hemotoxicity in vivo. In support 
of this postulate, we recently demonstrated that 5-HPQ is directly hemolytic in rat red 
cells; that is, when rat 51Cr-Iabeled-red cells are incubated with 5-HPQ in vitro for 2 hrs at 
37°C and then given intravenously to isologous rats, the tagged red cells are removed 
rapidly from the circulation (Bowman et aI., 2004). Loss of erythrocyte viability in vivo 
was associated with oxidative stress responses in vitro, including methemoglobin 
formation, depletion of erythrocytic GSH and formation of glutathione-protein mixed 
disulfides. Furthermore, when erythrocytic GSH was partially depleted (by 95%) by 
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titration with diethyl maleate (OEM) to mimic human G6PO deficiency, the hemolytic 
activity of 5-HPQ was enhanced in the rat erythrocytes by more than 5-fold. 
The potency and pro-oxidant nature of the hemolytic activity of 5-HPQ in rats 
supports its role as a major contributor to primaquine-induced hemolytic anemia; 
however, little is known about the fate of these erythrocytes in vivo; i.e., do they undergo 
intravascular lysis and uptake of the cell fragments into the liver, or do the cells remain 
intact and undergo selective uptake into the spleen? In addition, the role of macrophages 
in the process of removal of damaged erythrocytes has been presumed, yet no data exist 
that demonstrate a requirement for phagocytic activity in order to provoke a hemolytic 
response. 
The present studies were undertaken to determine the fate of 5-HPQ-treated erythrocytes 
in rats, and to clarify the role of macrophages in this process. Experimentally, we have 
compared uptake of 5-HPQ-treated erythrocytes into the spleens and livers of normal rats 
with that of rats pretreated with clodronate-Ioaded liposomes. This pretreatment is known to 
deplete splenic macrophages and hepatic Kupffer cells (Van Rooijen and Sanders, 1994). We 
report that 5-HPQ-treated slCr-Iabeled erythrocytes are rapidly taken up into the spleen in 
preference to the liver when re-administered intravenously to untreated rats. In clodronate-
loaded liposome pretreated rats, the survival of the 5-HPQ damaged red cells in the 
circulation was markedly prolonged, coinciding with a virtual abolition of splenic uptake and 
a much delayed hepatic uptake. Parallel studies using J774A.1 macrophage cultures 
demonstrated the uptake of 5-HPQ-damaged, but visually intact, rat red cells into "jackpot" 
cells in the culture (Cocco and Ucker, 2001). The uptake was concentration-dependent in 
regard to 5-HPQ, and was enhanced markedly by prior depletion of erythrocytic GSH by 
DEM titration. The data indicate that the premature removal of 5-HPQ-damaged red cells in 
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the rat results from their selective recognition and uptake by splenic macrophages. Of 
importance, the reproduction of the in vivo macrophage-dependent toxicity in vitro indicates 
that the 1774A.l macrophage culture can be used as a model to look for external cell surface 
markers that initiate splenic sequestration of erythrocytes inflicted with hemolytic injury. 
Materials and Methods. 
Chemicals and materials. 
5-HPQ was synthesized by HBr-catalyzed hydrolysis of 5-methoxyprimaquine as 
described previously (Bowman et aI., 2004). Na/1Cr04 in sterile saline (ImCi/ml, pH 8) 
was obtained from New England Nuclear (Billerica, MA). Phosphatidylcholine (1,2-
diacyl-sn-glycero-3-phosphocholine), cholesterol and clodronate (dichloromethylene 
bisphosphonate) were purchased from Sigma-Aldrich (St. Louis, MO). 1774A.l cells are 
a monocyte-derived murine macrophage cell line that was obtained from the ATCC 
(Manassas, VA). All other reagents were of the best grade commercially available. 
Animals and erythrocyte incubation conditions. 
Male Sprague-Dawley rats (75-100 g) were purchased from Harlan (Indianapolis, IN) 
and maintained on food and water ad libitum. Animals were acclimated for 1 week to a 
12-h light/dark cycle before their use. Blood from the descending aorta of anesthetized 
rats was collected into heparinized tubes and washed three times with HBSS (with Ca2+ 
and Mg2+) to remove the plasma and buffy coat. The cells were resuspended to a 40% 
hematocrit in HBSS and used the same day they were collected. Stock solutions of 5-
HPQ in argon-purged water were prepared to deliver the appropriate concentrations of 5-
HPQ in 10 pI to erythrocyte suspensions (1-3 ml). 
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In some experiments, diethyl maleate (DEM) was used to deplete aSH (>95%) in 
erythrocyte suspensions as described previously (Bolchoz et aI., 2002b). Briefly, DEM 
(750 pM) dissolved in acetone was added to packed red cells. After 15 min of incubation 
at 37°C, the content of erythrocytic aSH was determined from an aliquot by HPLC-EC. 
Preparation and administration of clodronate-loaded liposomes. 
Clodronate-Ioaded liposomes were prepared as described previously (Van Rooijen 
and Sanders, 1994). The liposomes were washed once and centrifuged to remove free 
clodronate, and the liposomes were administered intravenously (0.1 mllIO g body wt) via 
the tail vein to rats 24 hr before administration of the radiolabeled erythrocytes. 
Intravenous administration of saline served as a control to ensure that these animals had 
normal, non-blocked, non-suppressed and non-activated macrophages. 
Measurement of erythrocyte disposition in vivo. 
The survival and fate of erythrocytes was determined in saline-treated or clodronate-
loaded liposome-treated rats after in vitro exposure to 5-HPQ as described previously 
(Bowman et aI., 2004). Briefly, StCr-Iabeled erythrocytes were incubated with 5-HPQ (40 
pM) for 2 h at 37°C. After incubation the erythrocytes were washed once and 
resuspended in HBSS (40% hematocrit). Aliquots (0.5 ml) of the labeled cells were 
administered intravenously to isologous rats. To blood samples (75 pI) were taken from 
the orbital sinus 1 hr after administration of labeled red cells. Additional blood samples 
were taken at 48 hr intervals for 7 days. At the end of the experiment, the samples were 
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counted in a well-type gamma counter and the data are expressed as a percentage of the 
To blood sample. 
To determine the disposition of the SICr label, livers and spleens were excised at 
designated intervals from groups of rats that had received the labeled erythrocytes as 
described above. The tissues were weighed and then counted concurrently in a well-type 
gamma counter, and the values were corrected for 5ICr activity of residual erythrocytes 
within the tissue vasculature. In experiments to determine the disposition of broken red 
cells, untreated 5ICr-Iabeled erythrocytes (40% hematocrit) were subjected to three 
freeze-thaw cycles using a dry ice-acetone bath to induce complete cell lysis. Aliquots of 
the (unwashed) broken cell preparation were administered intravenously to rats in the 
same manner as described above for the intact erythrocytes. 
Measurement olin vitro erythrophagocytosis. 
J774A.1 macrophages were plated in 12-well culture plates at 2 x 105 cells/well to 
prepare semiconfluent monolayers. Twenty-four hours after plating the macrophages, 
aliquots (50 JlI) of control and 5-HPQ-treated 5Ier-Iabeled packed erythrocytes (treated as 
described above) were added to the macrophage cultures and allowed to incubate for up 
to 24 hr at 37°C. After incubation, non-ingested erythrocytes were removed by washing 
once with NH4CI (0.8% w/v) followed by washing three times with HBSS. The adherent 
macrophages were released from the plates with 0.5 ml NaOH (0.5 N), and the extent of 
phagocytosis was assessed by counting the radioactivity in the macrophages using a well-
type gamma counter. 
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Results 
Disposition of51Cr-labeled erythrocytes after in vitro exposure to 5-HPQ. 
Although the direct hemolytic activity of 5-HPQ in rats has been established 
(Bowman et aI., 2004), the fate of 5-HPQ-damaged red cells in vivo; i.e., intravascular 
lysis vs. splenic sequestration, is unknown. To determine the anatomic site(s) of 
sequestration of 5-HPQ-damaged red cells and the role of macrophages in this process, 
rat 5lCr-Iabeled erythrocytes were incubated with 5-HPQ (40 ltM) for 2 hr at 37°C. After 
the incubation, the erythrocytes were washed and returned to the circulation of saline-
pretreated or clodronate-Ioaded liposome-pretreated rats. At designated intervals a blood 
sample was taken from each rat followed by excision of the spleen and liver for 
determination of uptake of the radiolabeI. 
Upon readministration to saline-pretreated rats, 5-HPQ-treated erythrocytes showed 
an initial rapid disappearance from the circulation (Fig. 3.1A). This loss of blood 
radioactivity coincided with a marked increase in splenic radioactivity (Fig. 3.1B), which 
was not observed in rats that received saline-treated control cells. The splenic 
radioactivity reached an apparent steady state by day 1 corresponding to processing of the 
tagged red cells and subsequent release of the radioactivity for urinary excretion (data not 
shown). The levels of radioactivity in the livers of rats given 5-HPQ-treated erythrocytes 
were slightly higher than those in the controls (Fig. 3.1B), and these levels remained 
constant over the course of the experiment. On a whole organ basis, splenic radioactivity 
in saline-pretreated rats was 4 to 5 times that of the liver and 50 to 60 times higher when 
expressed per gram of tissue. 
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In contrast to the rapid disappearance of blood radioactivity in saline-pretreated rats, 
the rate of removal of 5-HPQ-treated erythrocytes in rats pretreated with clodronate-
loaded liposomes was markedly reduced (Fig. 3.2A), and was not accompanied by 
significant uptake of radioactivity into the spleen (Fig. 3.2B). As shown in Fig. 3.3A, the 
decreased rate of removal of blood radioactivity was associated with a time-dependent 
decrease in the spleen/body weight ratio (40% decrease at day 7), which presumably 
reflects extensive depletion of macrophages from this tissue. Administration of 
clodronate-Ioaded liposomes had no effect on liver/body weight ratio (Fig. 3.3B). The 
amount of 5ICr detected in the livers of rats pretreated with saline or clodronate-Ioaded 
liposomes was relatively low, suggesting that under normal conditions, hepatic Kupffer 
cells do not have an active role in removing 5-HPQ-damaged erythrocytes. Of note, the 
clodronate-Ioaded liposome-pretreated rats showed a significant increase in liver 
radioactivity on day 7 (Fig. 3.2B), which suggests that Kupffer cells may have begun to 
repopulate the Ii ver and remove damaged erythrocytes in the absence of a functional 
splenic uptake mechanism. This observation is in agreement with previous studies which 
showed that Kupffer cells repopulate the liver after liposome treatment more rapidly than 
macrophages repopulate the spleen (Van Rooijen et aI., 1990). Although uptake into the 
liver may be considered to reflect intravascular lysis of erythrocytes, it has been shown 
that Kupffer cells will take on the role of removing senescent and damaged erythrocytes 
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Fig. 3.1. Disposition of the SICr label in (A) blood and (B) spleens and livers of rats 
infused with slCr-Iabeled erythrocytes exposed in vitro to the vehicle (.) or 40 }lM 5-
HPQ (_) for 2 hr at 37°C. Data points are means ± S.D. (n = 3). 
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liposomes (open symbols) on the disposition of the 51Cr label in (A) blood and (B) 
spleens and livers of rats infused with 51Cr-labeled erythrocytes exposed in vitro to the 
vehicle (circles) or 40 JlM 5-HPQ (squares) for 2 hr at 37°C. Data points are means ± 
S.D. (n = 3). 
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Fig. 3.3. Effect of pre-treatment of rats with clodronate-Ioaded liposomes on (A) spleen 
and (B) liver weight/body weight ratios. Rats were given saline (e) or clodronate-Ioaded 
liposomes (0) intravenously. At the indicated time points, the spleens and livers were 
excised and weighed. Data points are means ± S.D (n = 3). *Significantly different from 
PBS-pretreated rats (p < 0.05). 
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Disposition 0/51 Cr-Iabeled broken cells in vivo. 
To determine if intravascular lysis could have contributed to the hemolytic response 
to 5-HPQ, the disposition of untreated 5ter-Iabeled broken red cells was examined. 
Broken erythrocytes were prepared by subjecting 51Cr-tagged cells to multiple freeze-
thaw cycles. As shown in Fig. 3.4A, rapid and complete disappearance of the 5ter-Iabel 
from the blood occurred within 2 days, and the loss of blood radioactivity was 
accompanied by a modest increase in liver radioactivity that probably reflects uptake of 
red cell fragments by Kupffer cells (Fig. 3.4B). In contrast to 5-HPQ-treated erythrocytes, 
only a minor amount of radiolabel from the broken cells was taken up into the spleen. 
About 30% of the administered radioactivity appeared in the urine during the seven-day 
observation period; the remainder was unaccounted for and was presumed to be occluded 
within the microcirculation. 
Role o/macrophages on the hemotoxicity of 5-HPQ in vitro. 
To determine whether splenic macrophage-dependent uptake of 5-HPQ-treated 
erythrocytes could be reproduced in vitro, ingestion of 5lCr-labeled rat erythrocytes was 
assessed using 1774A.1 cells, a mouse monocyte-derived macrophage cell line that has 
been shown previously to bind and ingest both necrotic and apoptotic cells (Cocco and 
Ucker, 2001). Radiolabeled erythrocytes were incubated with hemolytic concentrations 
of 5-HPQ for 2 hr at 37°C. The erythrocytes were then washed and incubated with 
macrophages for various time periods. At the end of each incubation period, the 
macrophages were rinsed with HBSS to remove non-adherent erythrocytes, and then 
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Fig. 3.4. Disposition of the Sier label in (A) blood of rats infused with Ster-Iabeled 
normal (e ) and broken (~) erythrocytes and in (B) the spleens (D), livers (0) and urine 
(~) of rats infused with Ster-Iabeled broken erythrocytes. Data points are means ± S.D. (n 
= 3). 
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As shown in Fig. 3.5, there was a concentration-dependent increase in radioactivity 
associated with the macrophages after 18 hr of incubation. The level of radioactivity 
associated with the macrophages at earlier time points (6 and 12 hr) was not significantly 
different from the controls (data not shown). Of importance, the concentration 
dependence for this response coincided with the concentration dependence for hemolytic 
acti vi ty in vivo. 
Visual confirmation of the phagocytic response was carried out by microscopic 
examination of the macrophages after 18 hr of incubation and prior to red cell lysis with 
ammonium chloride. In cultures containing control erythrocytes, only an occasional red 
cell could be observed within some of the macrophages (Fig. 3.6A). In contrast, large 
numbers of intact erythrocytes could be observed within many of the macrophages that 
received 5-HPQ-treated erythrocytes (Fig. 3.6B). Of note, a subset of the J774A.l 
macrophages appeared to account for a majority of the uptake of the damaged red cells. 
This phenomenon has been observed previously and suggests that within the clonal 
population, some macrophages, designated "jackpot cells," are more competent at 
erythrocyte recognition than are others. The mean values for macrophage radioactivity 
incorporate macrophages that have ingested no erythrocytes and others that contain 
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Fig. 3.5. Effect of 5-HPQ on the uptake of rat 51Cr-Iabeled red cells by 1774A.1 
macrophages. 51Cr-Iabeled erythrocytes were incubated with the indicated concentrations 
of 5-HPQ for 2 hr at 37°C. The erythrocytes were then washed and added to 1774A.l 
macrophage cultures for 24 hr. The cultures were washed with saline and ammonium 
chloride to remove unbound and bound (but non-ingested) erythrocytes, respectively. The 
macrophages were then scraped from the plates and the radioactivity was counted. Data 
points are means ± S.D. (n=3). *Significantly different from controls (p < 0.01). 
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Fig. 3.6. Light micrographs of J774A.l macrophage cultures after incubation with (A) 
control and (B) 5-HPQ-treated rat erythrocytes. Rat erythrocytes were treated with the 
vehicle or 5-HPQ (50 JlM) for 2 hr at 37°C before being incubated with the macrophages 
for 18 hr. The arrows indicate the presence of intact 5-HPQ-treated erythrocytes within 
jackpot cells." Magnification 63x. 
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Effect of GSH depletion on phagocytic uptake. 
G6PD-deficient individuals have long been known to have an enhanced susceptibility 
to primaquine-induced hemolytic anemia. We have shown previously that this enhanced 
susceptibility can be reproduced by prior depletion of red cell aSH (Bolchoz et aI., 2002; 
Bowman et aI., 2004). In the case of 5-HPQ, the hemolytic susceptibility of GSH-
depleted rat erythrocytes is about 5-fold greater than aSH-normal red cells in response to 
treatment with 5-HPQ (Bowman et aI., 2004). To determine the effect of aSH depletion 
on phagocytic removal in vitro, 5lCr-Iabeled erythrocytes were titrated with diethyl 
maleate to deplete aSH (ca. 95%) prior to exposure to a low concentration of 5-HPQ. 
After 2 hr of incubation at 37°C, control and aSH-depleted erythrocytes were incubated 
with J774A.l macrophages for 18 hr. As shown in Fig. 3.7, treatment of aSH-normal 
erythrocytes with 25 llM 5-HPQ did not induce a significant increase in phagocytic 
uptake by macrophages as compared with the control. However, the aSH-depleted 
erythrocytes showed a significant increase in their phagocytic uptake as compared with 
the control. This observation is in agreement with the previous in vitro exposure/ in vivo 
erythrocyte survival study (Fig. 2.10), which showed that 25 llM 5-HPQ was sub-
hemolytic in aSH-normal erythrocytes but was hemolytic in aSH-depleted erythrocytes 
(Bowman et aI., 2004). 
Discussion 
Human erythrocytes have a predetermined lifespan in the circulation of 
approximately 120 days. During this time, damage is thought to accumulate within 
erythrocytes to the point that these cells are recognized as senescent and are removed 
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Fig. 3.7. Effect of depletion of erythrocytic GSH on uptake of 5-HPQ-treated 
erythrocytes by J774A.l macrophages. slCr-Labeled erythrocytes were titrated with DEM 
to deplete GSH by 95%. GSH-normal and GSH-depleted erythrocytes were then 
incubated with the vehicle or 5-HPQ (25 pM) for 2 hr at 37°C. The erythrocytes were 
then washed and incubated with J774A.l macrophages for 18 hr. Data points are means ± 
S.D. (n=4). *Significantly different from controls (p < 0.05). 
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billion senescent erythrocytes are removed from the circulation per day by this system, 
surprisingly little is known about the changes red cells undergo as they age or the mechanism 
by which these cells are recognized and removed from the circulation (J andl, 1996). 
Studies supporting specific mechanisms are numerous and often conflicting, but most 
have in common the idea that an accumulation of damage to the membrane (in some form 
or another) occurs as a consequence of normal chronic, low-level oxidative stress (Clark 
et aI., 1984). How intracellular oxidative stress might provide a signal for phagocytic 
uptake is not understood, however, a number of theories have been proposed. 
On the one hand, oxidative stress may stimulate erythrocyte phagocytosis through a 
non-specific mechanism referred to as "culling". In this process, oxidative stress is 
thought to alter the membrane cytoskeleton leading to a decrease in erythrocyte 
deformability, thereby restricting progress of erythrocytes through the splenic red pulp 
and increasing their exposure to resident macrophages (Chadbum, 2000). On the other 
hand, oxidative stress may induce discrete changes to the external cell surface that 
stimulate specific phagocytic receptors on macrophages. Although what constitutes a 
recognition ligand on the erythrocyte surface is not yet known, extensive studies have 
supported several competing viewpoints, including: 1) unmasking of a cryptic antigenic 
site leading to opsonization by circulating autologous IgG (Kay, 1994); 2) unmasking of 
carbohydrate epitopes by desialization of glycoproteins, such as glycophorin A (Kay, 
1993); 3) extemalization of the membrane phospholipid, phosphatidylserine (MandaI et 
aI., 2002); and 4) loss of self recognition caused by alterations in the cell surface 
expression or lateral distribution of the macrophage inhibitory ligand, CD47 (Oldenborg 
et aI., 2000). 
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As part of ongoing studies in our laboratory to identify redox-active metabolites of 
primaquine that contribute to its hemotoxicity, we have demonstrated that a phenolic 
metabolite, 5-HPQ, is a direct-acting hemolytic agent in the rat (Bowman et aI., 2004). 
More specifically, we have shown that treatment of erythrocytes with 5-HPQ in vitro 
induces a GSH-dependent acceleration in the removal of the treated red cells in vivo. The 
present studies were undertaken to determine the fate of these erythrocytes and to 
ascertain whether splenic macrophages playa significant role in this process. 
To determine the fate of 5-HPQ-treated erythrocytes in vivo, we compared the extent 
of uptake of control, broken and 5-HPQ-treated erythrocytes into the spleen and liver, 
which are the two major organs for erythrocyte clearance. Broken red cells and 
erythrocytes exposed to 40 }lM 5-HPQ in vitro were both removed rapidly from the 
circulation as compared to the control. However, radioactivity from the broken cells was 
distributed to the liver and was ultimately recovered in the urine (Fig. 3.4B), whereas the 
radiolabel from 5-HPQ-treated erythrocytes was distributed primarily to the spleen (Fig. 
3.1 B). These data indicate that the spleen is the primary anatomic site of sequestration for 
erythrocytes exposed to 5-HPQ, and suggest that intravascular lysis does not contribute 
significantly to the loss of erythrocytes from the circulation. A similar observation was 
reported in G6PD-deficient individuals receiving primaquine (Degowin et aI., 1966). 
Those studies demonstrated that the radiolabel was taken up into both the spleen and the 
liver; however, the role of the spleen was significantly greater when uptake was 
expressed relative to organ weight. Importantly, these observations lend further support 
to the hypothesis that 5-HPQ has the requisite properties to mediate primaquine toxicity 
in vivo. 
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The selective depletion of macrophages from specific tissues has been shown to be 
beneficial for the determining their role in defined biological processes (Van Rooijen and 
Sanders, 1994). Macrophages have long been thought to be responsible for the splenic 
sequestration that is observed following administration of hemolytic agents. If 
macrophages are the key players and erythrocyte removal is not due simply to non-
specific trapping in the splenic cords, then substances that cause a loss of macrophage 
viability or otherwise interfere with the recognition mechanism should have an inhibitory 
effect on splenic sequestration. To test the dependence of the hemolytic response on the 
presence of functional macrophages, rats were given clodronate-Ioaded liposomes 24 hr 
before administration of the radioalabeled erythrocytes. After being ingested the 
liposomes are degraded within macrophages by lysosomal phospholipase, releasing 
clodronate into the cytosol where it induces macrophage cell death by apoptosis (Van 
Rooijen and Sanders, 1994). A dose of 0.1 ml of clodronate-liposome suspension per 10 
g body weight has been reported to be sufficient for depletion of splenic macrophages 
and hepatic Kupffer cells, and the decline in spleen/body weight ratio observed over the 
course of the experiment (Fig. 3.3) is consistent with selective loss of macrophages from 
the spleen. 
The time it takes to remove 50% of the sler-Iabeled erythrocytes for 5-HPQ-treated 
erythrocytes in clodronate-Ioaded liposome-pretreated rats was significantly delayed (by 
-3 days) in relation to that of the saline-pretreated rats (Fig. 3.2A). In addition, the 
accumulation of radioactivity that was observed in the spleens of saline-pretreated rats 
was markedly reduced in clodronate liposome-pretreated rats (Fig. 3.2B). Interestingly, 
uptake of the label into the livers of clodronate liposome-pretreated animals increased 
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significantly 4 days after administration of the labeled cells (Fig. 3.2B). This observation 
is in agreement with previous studies which showed that Kupffer cells repopulate the 
liver more rapidly than macrophages repopulate the spleen following treatment with the 
liposomes (Van Rooijen and Van Kesteren-Hendrikx, 2003), and it reflects the ability of 
Kupffer cells to increase their phagocytic activity towards erythrocytes in the absence of 
a functional splenic uptake mechanism (Ganick et aI., 1977). 
An in vitro assay for hemolytic anemia has long been desired. Although the rat 51Cr_ 
labeled erythrocyte in vitro exposure/in vivo survival assay (e.g., Fig. 3.1A) is a useful 
experimental tool for identifying direct-acting hemolytic agents and for studying the 
mechanism underlying the hemolytic response, this assay is limited by the need for large 
numbers of animals, it does not easily permit erythrocyte-macrophage interactions to be 
examined in detail, and it offers no way to investigate the hemolytic response in human 
erythrocytes. Measurement of drug-induced erythrocyte lysis in the test-tube (i.e., 
osmotic fragility) is not a valid substitute for the hemolytic response in vivo because of 
the recognition that the toxic endpoint is splenic sequestration. Efforts to develop cell 
culture assays based on isolated splenic macrophages or Kuppfer cells are hindered by 
the low numbers of cells that can be harvested from these tissues. 
In an effort to reproduce in vitro the uptake of 5-HPQ-treated erythrocytes that was 
observed in vivo, the phagocytic activity of murine monocyte-derived macrophage cell 
lines towards control and 5-HPQ-treated erythrocytes was examined. In initial 
experiments we utilized RAW 264.7 macrophages, but they did not respond to 5-HPQ-
treated erythrocytes (data not shown), though these cells did ingest erythrocytes that had 
been treated with neuraminidase (which cleaves sialic acid residues). In contrast, 1774A.l 
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macrophages were found to respond selectively to 5-HPQ-treated erythrocytes. Uptake of 
the StCr label by these macrophages was dependent on the concentration of 5 ... HPQ (Fig. 
3.5), and this concentration-dependence correlated closely with that of the hemolytic 
response (Bowman et aI., 2004). Importantly, uptake of the SICr label was due to 
phagocytosis of intact erythrocytes (Fig. 3.6), which supports the conclusion that 
erythrocyte removal in vivo is due to uptake of intact erythrocytes rather than to 
intravascular lysis. Moreover, the data suggest that restrictive passage of erythrocytes 
through the splenic architecture may not be necessary for removal of the damaged cells 
from the circulation. 
To test the validity of this cell culture system as an experimental model for 5 ... HPQ-
induced hemolytic anemia, the effect of depletion of erythrocyte aSH on phagocytic 
uptake was examined. In agreement with previous studies (Bowman et aI., 2004), aSH 
depletion induced the uptake of erythrocytes that were treated with a sub-hemolytic 
concentration of 5-HPQ in GSH-normal erythrocytes (Fig. 3.7). Taken together, these 
data indicate that 1774A.l macrophages can be used as a valid model to identify cell 
surface changes that signal macrophage recognition and phagocytosis. 
For many years, "pitting" and "culling" have been commonly accepted mechanisms 
for the functional removal of oxidatively damaged red cells by the spleen. "Culling" is 
thought to occur as damage to the red cell results in increased transit time through the 
tight meshwork of the splenic red pulp, which increases the likelihood of exposure to and 
recognition by cordal macrophages (Chadburn, 2000). Possible mechanisms of trapping 
that have been suggested include: 1) that the hemoconcentration that occurs in the splenic 
red pulp creates an acidic, hypotonic environment that results in cell swelling and 
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trapping within the splenic meshwork; or 2) that removal is directly related to profound 
morphological alterations and/or damage to the red cell membrane that renders them less 
flexible and thus more susceptible to becoming trapped (Chadburn, 2000). "Pitting" is 
thought to lead to the removal of damaged cells as cell inclusions or appendages, such as 
Heinz bodies, cause parts of the red cell to be trapped in the sinus wall and subsequently 
amputated by macrophages, allowing the pliant part of the cell to slip through. Although 
the cell survives, it does so with a reduction of membrane surface, which can ultimately 
lead to spherocytosis and trapping in the spleen. Erythrophagocytosis by J774A.l 
macrophages in vitro provides evidence that "pitting" and "culling" are not necessary for 
the recognition of 5-HPQ-damaged red cells. Although a role for culling cannot be ruled 
out, since it could still work by increasing the time of exposure of damaged red cell to 
macrophages, it is likely that the macrophages recognize a specific signal on the red cell 
surface rather than a general structural alterations. 
In summary, we have demonstrated that splenic macrophages play a crucial role in 
the removal of 5-HPQ-treated rat red cells from the circulation, and that this response can 
be reproduced in vitro using J774A.l macrophages. This observation further supports the 
notion that 5-HPQ is an important contributor to the hemolytic response induced by 
primaquine. Future studies are warranted to determine the nature of the signal that 
commits the damaged erythrocytes to premature splenic sequestration .. 
CHAPTER 4 
Primaquine-Induced Hemolytic Anemia: Role of Membrane Lipid 
Peroxidation and Cytoskeletal Protein Alterations on the 
Hemotoxicity of 5-Hydroxyprimaquine 
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Introduction 
Malaria is a life-threatening parasitic disease of epidemic proportions, and it is a 
major public health concern for developing countries. Each year malarial infection is 
responsible for an estimated 300-500 million acute illnesses and 2 million deaths in 
tropical and subtropical regions worldwide (Kain and Keystone, 1998). Primaquine, the 
prototype 8-aminoquinoline tissue schizontocide, is effective against all four malarial 
species that infect humans and is the only drug approved for the radical cure of relapsing 
malaria. As resistance has developed from extensive use of blood schizontocides, such as 
chloroquine, the importance of primaquine in combating multiple drug resistance has 
increased, and it is now used in combination with several blood schizontocides for the 
treatment and prophylaxis of all forms of malaria, including the most lethal malarial 
species, Plasmodiumfalciparum (Shanks et aI., 2001). Primaquine is also effective in the 
treatment of Pneumocystis carinii pneumonia, a common infection in AIDS patients 
(Toma et aI., 1998). The clinical utility of primaquine, however, is restricted by its 
hemotoxicity, particularly in patients who are genetically deficient in erythrocytic 
glucose-6-phosphate dehydrogenase (G6PD) activity (Beutler, 1990). 
The hemolytic activity of primaquine has long been known to be due to an intra-
erythrocytic oxidative stress that is mediated by redox-active metabolites rather than by 
the parent drug itself. The oxidatively damaged erythrocytes are thought to be recognized 
by splenic macrophages as the equivalent of senescent red cells, resulting in their 
selective removal from the circulation (Rifkind, 1966). 5-Hydroxyprimaquine (5-HPQ) is 
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a putative human metabolite of primaquine that forms a redox pair with its quinoneimine 
form; continuous cycling of this redox pair is thought to generate reactive oxygen species 
(ROS) within erythrocytes (Vasquez-Vivar and Augusto, 1992). We have shown that 
when 5-HPQ is incubated with rat red cells in vitro, damage occurs within the cells such 
that they are removed rapidly from the circulation of isologous rats as compared to 
untreated controls (Bowman et aI., 2004). While it is clear that ROS attack on the 
cytosolic surface of the membrane leads to a signal for removal of damaged erythrocytes 
from the circulation, neither the nature of the crucial target(s), whether lipid or protein~ 
nor the mechanism of transfer of the signal across the membrane is known. 
The mechanism(s) by which senescent or damaged (but intact) erythrocytes are 
selected for splenic sequestration are not known. Two current hypotheses are: 1) that red 
cell damage is analogous to the apoptotic response observed in other (nucleated) cell 
types, resulting in changes to the normal asymmetric distribution of phospholipids 
(MandaI et aI., 2002); and 2) that protein oxidation interferes with normal protein-protein 
interactions among the cytoskeletal, integral membrane and cell surface proteins that 
confer the recognition of "self' (Oldenborg et aI., 2000; Bruce et aI., 2003). The present 
study examines the role of the postulated truncated apoptotic pathway in the hemolytic 
activity of 5-HPQ, specifically in regard to potential roles for membrane lipid 
peroxidation and loss of phospholipid (i.e., phosphatidylserine) asymmetry. We also 
address the alternate hypothesis, that alterations to skeletal membrane proteins in 5-HPQ-
damaged red cells provide a crucial link between internal oxidative stress and external 
recognition and removal of erythrocytes from the circulation. 
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The data indicate that under in vitro incubation conditions that provoke premature 
splenic sequestration of red cells in vivo, 5-HPQ generates intracellular ROS but does not 
induce lipid peroxidation or cause loss of phosphatidylserine asymmetry in the plasma 
membrane of the red cell. In contrast, profound alterations occur to certain proteins of the 
cytoskeleton in 5-HPQ-treated erythrocytes, and these alterations are due primarily to the 
formation of disulfide-linked hemoglobin-skeletal protein adducts. Further studies are 
warranted to determine the specific signal for erythrocyte phagocytosis, however, the 
present data are consistent with the concept that cytoskeletal protein damage, rather than 
alterations in the lipid bilayer, underlies the process of splenic uptake of red cells 
damaged during the course of primaquine therapy. 
Materials and Methods 
Chemicals and materials. 
5-HPQ was synthesized by HBr-catalyzed hydrolysis of 5-methoxyprimaquine as 
described previously (Bowman et aI., 2004). Bovine factor V, bovine factor Xa and 
bovine prothombin were obtained from Enzyme Research Laboratories (South Bend, IN). 
Chromogenic substrate S-2238 was purchased from Chromogenix (DiaPharma Group, 
Inc., Westchester, OH). Alexafluor 647-conjugated annexin V and 2' ,7'-dichloro-
dihydrofluorescein diacetate (DCFDA) were obtained from Molecular Probes, Inc. 
(Eugene, OR). Calcium ionophore A23187, N-ethylmaleimide (NEM) , cumene 
hydroperoxide (CH) and rabbit anti-rat hemoglobin antibodies were purchased from 
Sigma-Aldrich (St. Louis, MO). All other reagents were of the highest grade 
commercially available. 
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Erythrocytes and incubation conditions. 
Male Sprague-Dawley rats (75-100 g) were obtained from Harlan Laboratories 
(Indianapolis, IN) and maintained on food and water ad libitum. Animals were 
acclimated for 1 week to a 12-h light/dark cycle before their use. Blood was collected 
from the descending aorta of anesthetized rats into heparinized tubes and washed 3 times 
with Hanks' Balanced Salt Solution with calcium (HBSS, Invitrogen, Carlsbad, CA) to 
remove the plasma and buffy coat. The cells were resuspended to a 40% hematocrit in 
HBSS and used on the same day they were collected. Erythrocytes were washed 3 times 
with HBSS and resuspended to a 40% hematocrit. 
Stock solutions of 5-HPQ in argon-purged water were prepared to deliver the 
appropriate concentration of 5-HPQ in 10 pI to erythrocyte suspensions (1-2 ml). The 
erythrocyte suspensions (40% hematocrit) were allowed to incubate for up to 2 hr at 
37°C, and then washed once with HBSS prior to biochemical analyses. The effects of 
DTT on intact red cells were determined as follows: 1.) red cells in PBSG were 
incubated for the indicated times up to forty minutes in the presence or absence of 50pM 
5-HPQ; 2.) Cells were washed once with PBSG and reincubated for 1 additional hour in 
the presence or absence of 5 mM DTT; 3.) at the end of the incubation with DTT, the red 
cells were washed once again with PBSG and prepared for the appropriate assay as 
described below. 
Measurement of ROS formation in erythrocytes. 
Rat erythrocytes were suspended in isotonic phosphate-buffered saline (pH 7.4) 
supplemented with 10 mM D-glucose (PBSG) to a 10% hematocrit. DCFDA (600 pM), 
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dissolved in DMSO, was added to the erythrocyte suspension and allowed to incubate for 
15 min at 37°C. Immediately after the addition of various concentrations of 5-HPQ, 
fluorescence was measured at 2 min intervals for 20 min (excitation 488 nrn, emission 
529 nm) on a Molecular Devices SprectraMAX Gemeni XS Fluorescence Microplate 
Reader (Molecular Devices, Sunnyvale, CA). 
Preparation of erythrocyte membrane ghosts. 
Red cell ghosts were prepared from vehicle- and 5-HPQ-treated red cells as described 
previously with modification (Grossman et aI., 1992). Briefly, washed red cells were 
centrifuged and the packed cells were lysed in 30 ml of ice-cold phosphate buffer (5 mM, 
pH 8.0). The membrane ghosts were pelleted by centrifugation at 20,000 x g for 10 min. 
The supernatant was removed by aspiration and the ghosts were repeatedly washed with 
phosphate buffer until the control cells yielded white ghosts, typically 3-4 washes. 
Determination of lipid peroxidation in erythrocytes. 
Lipid peroxidation was assessed by measuring the content of F2-isoprostanes in red 
cell ghosts prepared from vehicle- and 5-HPQ-treated red cells as described previously 
(Bolchoz et aI., 2002b). Briefly, the lipids were extracted from membrane ghost 
suspensions (250 }ll), prepared with argon-purged phosphate buffer, with 
chloroform/methanol (2: 1, v/v). The extracted lipids were then subjected to alkaline 
hydrolysis to release the esterified F2-isoprostanes. The work-up procedure for 
quantifying F2-isoprostanes by GC/MS is described in detail elsewhere (Morrow and 
Roberts, 1999). Treatment of red cell suspensions for 1 hr at 37°C with the lipid-soluble 
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peroxide, cumene hydroperoxide (1 mM), was used as a positive control for lipid 
peroxidation (van den Berg et aI., 1992). 
NEM and calcium ionophore treatment of erythrocytes. 
As a positive control for translocation of phosphatidylserine from the inner to the 
outer leaflet of the lipid bilayer, rat erythrocytes were treated with NEM to inhibit 
aminophospholipid translocase, and calcium ionophore A23187 was added to induce 
membrane lipid scrambling as described previously (Kuypers et aI., 1996). Briefly, rat 
erythrocytes were washed three times with HBSS (with calcium) and reconstituted to 
40% hematocrit with HBSS. The red cell suspension (1 ml) was allowed to incubate with 
10 mM NEM for 30 min at 37°C, and then washed twice with HBSS. Calcium ionophore 
A23187 (4 }lM) in DMSO was then added and allowed to incubate for 1 hour at 37°C. 
After incubation, the red cells were washed with 2.5 mM EDTA (1 ml) to remove the 
calcium, and then washed twice more with calcium-free HBSS containing 1 % bovine 
serum albumin (BSA) to remove the ionophore. The cells were then re-suspended in 1 ml 
of annexin binding buffer (10 mM HEPES, 140 mM NaCI, and 2.5 mM CaCI2, pH 7.4), 
and analyzed for annexin V labeling and prothrombinase activity as described below. 
Determination of phosphatidylserine translocation in erythrocytes. 
Erythrocyte labeling with annexin V was performed according to a modification of a 
flow cytometric technique (Kuypers et aI., 1996). Following incubation with the vehicle, 
the positive control, or 5-HPQ (2 hr at 37°C), aliquots (50 }ll) of the suspensions were 
removed and washed twice with annexin binding buffer (1 ml). After the last wash, 
97 
aliquots of the packed red cells (2 Jil) were combined with annex in binding buffer (997 
Jil), and AlexaFluor 647 -conjugated annexin-V solution (1 Jil) was added to the 
erythrocyte suspensions to bring the total volume to 1 ml. After 30 min incubation in the 
dark at room temperature, the samples were washed and re-suspended in annexin binding 
buffer (1 ml), and analyzed on a Becton Dickinson FACSCalibur analytical flow 
cytometer (BD Biosciences, San Jose, CA). 
Phosphatidylserine translocation was also assessed by measuring the conversion of 
prothrombin to thrombin using a modification of a method described previously (Kuypers 
et aI., 1996). Briefly, after incubation with the vehicle or 5-HPQ, erythrocyte suspensions 
were washed once with HBSS, and 1 pI of packed cells was added to 1 ml of Tris buffer 
(pH 7.4) at 37°C. Bovine factor V (0.33 D/ml) and bovine factor Xa (0.33 D/ml) were 
added, followed by 0.13 mg of prothrombinase. After 4 min, the reaction was quenched 
with 15 mM EDTA. The erythrocytes were pelleted by centrifugation and 75 }ll of the 
supernatant was added to 1 ml of chromogenic substrate S-2238 working solution. The 
increase in absorbance at 405 nm was determined over 1 min at 37°C in a Shimadzu UV-
160 Spectrophotometer (Shimadzu Corporation, Kyoto, Japan) equipped with software 
for enzyme kinetics. The amount of thrombin formed per unit time was determined by 
comparison with thrombin standards. 
Electrophoretic analysis o/membrane cytoskeletal proteins. 
Red cell ghosts from control and 5-HPQ-treated erythrocytes were washed 
exhaustively to remove unbound hemoglobin (4 washes). The ghost protein was then 
solubilized in NuPAGE LDS Sample Buffer (Invitrogen, Carlsbad, CA), with or without 
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40 mM dithiothreitol (DTT), and heated at 70°C for 10 min. Solubilized proteins (15 jlg) 
were loaded and resolved on 4-12% NuPAGE Bis-Tris gels with MOPS Running Buffer 
(Invitrogen) at 200 V (constant) for 50 min. Resolved proteins were transferred to PVDF 
membranes for immunoblot analysis according to the Invitrogen protocol. For SDS-
PAGE analysis, solubilized membrane ghosts were resolved on continuous gels under 
non-reducing conditions as described previously (McMillan et aI., 1995), then stained 
with Gel Code Blue Stain Reagent (Pierce, Rockford, IL) and destained with water. 
Rat red cell membrane proteins were identified according to molecular weight 
(Fairbanks et aI., 1971) with the use of molecular weight protein standards (Invitrogen). 
Blotted proteins were blocked in TBST (pH 7.5) containing 5% non-fat dry milk and 
incubated in TBST containing 1 % BSA and primary antibody (rabbit anti-rat 
hemoglobin, 1: 10,000 vol/vol). After washing and incubation with the peroxidase-
conjugated secondary antibody (anti-rat IgG), the immunoblots were developed using 
ECL detection (Amersham Biosciences, Piscataway, NJ). 
GSH Depletion of Erythrocyte Suspensions. 
Diethyl maleate (DEM) was used to deplete aSH (>95%) in red cell suspensions as 
described previously (Bolchoz et aI., 2002b). Briefly, DEM (750}lM) dissolved in 
acetone was added to packed red cells. After a 15-min incubation at 37°C, the red cells 
were analyzed for aSH content by HPLC-EC. The cells were re-suspended to a 40% 
hematocrit in HBSS and used on the same day that they were collected. 
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Measurement of Hemolytic Activity. 
The survival of rat 51Cr-labeled red cells was determined in vivo after in vitro 
incubation with 50}lM 5-HPQ with or without 5mM DTT as described above. After 
incubation at the specified times at 37°C, the erythrocytes were washed once and 
resuspended in PBSG (40% hematocrit). Aliquots (0.5ml) were administered 
intravenously to isologous rats. To blood samples were taken from the orbital sinus xx 
min after administration of labeled red cells. Additional blood samples were at sequential 
times over 14 days. At the end of the experiment, the samples were counted in a well-
type gamma counter, and the data were expressed as a percentage of the To blood sample. 
The hemolytic response was quantified by calculating the fraction of radiolabeled red 
cells that were removed from the circulation within the first 48 hr for each animal by 
linear regression as described previously (McMillan et aI., 2001). Statistical significance 
was determined with use of Student's t test. 
Erythrophagocytosis by J774 macrophages. 
J774A.l macrophages (ATCC) were plated at 200,000 cells/well in 12 well culture 
plates and allowed to adhere. After 24 hr, 50}l1 Cr-Iabeled, vehicle- or 5-HPQ-treated 
packed red cells were added to the macrophage monolayer and incubated for 24 hr at 
37°C. Non-ingested RBCs were removed by lysis with NH4CI and washed three times 
with buffer. Adherent macrophages were released with NaOH and phagocytosis was 
assessed by measuring radioactivity in a well-type gamma counter. Data were expressed 
as either counts per minute (CPM) or as a percent of control. 
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Results 
Effect of 5-HPQ on ROS generation in rat erythrocytes. 
DCFDA is a lipid-soluble probe that can detect the intracellular formation of several 
types of ROS, including hydroxyl, peroxyl, alkoxyl, and nitroxyl free radicals, as well as 
peroxynitrite (Halliwell and Whiteman, 2004). To assess the formation of ROS in 5-HPQ-
treated rat erythrocytes, erythrocyte suspensions were pre-incubated with DCFDA for 15 
min followed by addition of 5-HPQ. Fluorescence was then measured at 2 min intervals 
for 20 min using a fluorescence microplate reader. Preliminary experiments indicated that 
the concentration of red cells in the suspensions had to be reduced from 40% to a 10% 
hematocrit to avoid significant quenching of the fluorescence signal by the cells. 5-HPQ 
concentrations were reduced accordingly (by 4-fold) to maintain the same 5-HPQ-to-red 
cell ratio that was used in the other experiments. 
As shown in Fig. 4.1, incubation of erythrocytes with DCFDA in the absence of 5-
HPQ resulted in a slight but measurable increase in fluorescence over a 20 min time 
period, consistent with the known low-level, steady production of ROS in normal red 
cells (Jandl et aI., 1960). Inclusion of 5-HPQ (5-30 pM) in the erythrocyte suspension 
caused a marked and concentration-dependent increase in the generation of fluorescence, 
indicating enhanced production of ROS by 5-HPQ. This observation is consistent with 
previous observations which showed that 5-HPQ has the ability to redox cycle and to 
cause oxidative stress in rat erythrocytes, as evidenced by aSH oxidation and 
methemoglobin formation (Bowman et aI., 2004). No fluorescence signal was detected in 
the absence of red cells or in the absence of DCFDA (data not shown). 
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Effect of 5-HPQ on erythrocyte membrane lipid peroxidation. 
To determine whether ROS production by 5-HPQ resulted in lipid peroxidation, rat 
red cells were incubated for 2 hr at 37°C with concentrations of 5-HPQ corresponding to 
EC lO (10 J-tM), ECso (40 J-tM) and EC90 (70 J.lM) concentrations for hemolytic activity 
(Bowman et aI., 2004). The red cells were then washed and lysed in argon-purged 
hypotonic buffer for the preparation of red cell ghosts, as described previously 
(Grossman et aI., 1992). Esterified isoprostanes were extracted from the ghosts and 
hydrolyzed, and the total F2-isoprostane content in the samples was quantified by GC-MS 
(Morrow and Roberts, 1999). As shown in Fig. 4.2, F2-isoprostane content in 5-HPQ-
treated incubates was not different from that of control incubates, regardless of the 
concentration of 5-HPQ. In contrast, treatment of red cells with the positive control, 
cumene hydroperoxide (CH, 1 mM), resulted in a 3-fold increase in F2-isoprostane 
formation. Treatment with this concentration of CH was the lowest that produced a 
significant elevation in F2-isprostane formation that was not associated with significant 
frank lysis of the erythrocytes; concentrations of CH greater than 1 mM caused 
progressive and complete red cell lysis (data not shown). 
Effect of 5-HPQ on red cell membrane phospholipid asymmetry. 
To determine whether exposure to 5-HPQ resulted in a loss of phosphatidylserine 
asymmetry, the transmembrane location of phosphatidylserine was assessed by two 
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Fig. 4.1. Effect of 5-HPQ on ROS generation in rat erythrocytes. Erythrocyte suspensions 
(10% hematocrit) were incubated with DCFDA (600 }lM) for 15 min. The red cells were 
then treated with the vehicle (e ), 5}lM (+ ), 15 }lM (~ ), and 30 }lM (_ ) 5-HPQ. 
Fluorescence emission intensity was monitored on a fluorescence microplate reader 
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Fig. 4.2. Effect of 5-HPQ on F2-isoprostane formation in rat erythrocytes. Erythrocytes 
were incubated for 2 hr at 37°C in HBSS containing the indicated concentrations of 5-
HPQ. After incubation erythrocyte ghosts were prepared and analyzed for F2-isoprostane 
content by GC-MS as described in the Materials and Methods. The values are means ± 
S.D. (n = 3). * Significantly different from control (p < 0.05). 
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Erythrocyte suspensions (40%) were incubated with hemolytic concentrations of 5-
HPQ (10 to 70 ,...,M) for 2 hr. At the end of the incubation, the red cells were washed, re-
suspended in HBSS and analyzed for prothrombinase activity, which is dependent on cell 
surface exposure to phosphatidylserine (Bevers et aI., 1982). For a positive control, 
erythrocytes were treated with 10 mM NEM for 30 min, followed by treatment with 4 
pM calcium ionophore A23187 in the presence of calcium for 1 hr. As shown in Fig. 
4.3A, thrombin formation in 5-HPQ-treated erythrocytes was not significantly different 
from the control. In contrast, the positive control, NEM plus ionophore and calcium, 
induced an 8-fold increase in prothrombinase activity as compared to the control. 
The presence of phosphatidy lserine in the outer leaflet of the lipid bilayer was 
confirmed by direct labeling of erythrocytes with fluorescently conjugated annexin V, 
which binds to acidic phospholipids, particularly phosphatidylserine (Kuypers et aI., 
1996). As shown in Fig. 4.3B, annexin-positive erythrocytes from 5-HPQ-suspensions 
constituted less than 2% of the red cells, which was similar to the vehicle-treated control. 
In contrast, treatment of red cells with NEM plus ionophore and calcium resulted in 
labeling of about 45% of the erythrocytes. 
Effect of 5-HPQ on rat erythrocyte membrane skeletal proteins. 
To determine whether 5-HPQ-induced hemolytic activity was associated with 
alterations to the membrane cytoskeleton, rat erythrocyte ghost proteins from control and 
5-HPQ-treated erythrocytes were separated by SOS-PAGE and either stained with Gel 
Code Blue, or transferred to PVDF membranes and immunostained with antibodies to rat 
hemoglobin. As shown in Fig. 4.4A, 5-HPQ caused concentration-dependent changes to 
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Fig. 4.3. Effect of 5-HPQ on phosphatidylserine asymmetry in rat erythrocytes. 
Erythrocyte suspensions (40% hematocrit) were incubated with the indicated 
concentrations of 5-HPQ for 2 hr at 37°C. NEM/Ca2+ was used as a positive control. (A) 
Prothrombinase activity and (B) AlexaFluor 647-conjugated annexin V labeling were 
determined as described in Materials and Methods. The values are means ± S.D. (n = 3). 
* Significantly different from control (p < 0.05). 
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the normal electrophoretic pattern of erythrocyte skeletal proteins as compared with that 
of the vehicle-treated control. 5-HPQ treatment induced the appearance of new protein 
bands at 16, 32 and 64 kDa, which is consistent with formation of membrane-bound 
hemoglobin monomers, dimers and trimers, respectively (Grossman et aI., 1992). In 
addition, there was a concentration-dependent loss of resolution of protein bands 1 and 2 
(a and B spectrins), splitting of band 2.1 (ankyrin) and loss of band 4.2. On the other 
hand, band 4.1 and band 5 (actin) appeared not to be affected significantly by treatment 
with 5-HPQ. 
Immunoblot analysis of the skeletal proteins from 5-HPQ-treated red cells showed a 
dramatic increase in the content of membrane-bound hemoglobin (Fig. 4.4B). Only 
insignificant amounts of hemoglobin were bound to skeletal proteins at sub-hemolytic 
concentrations of 5-HPQ «40 }lM), whereas increasing amounts of hemoglobin were 
bound to a wide variety of proteins at hemolytic concentrations. When 5-HPQ-treated 
ghosts were treated with DTT (40 mM C!t 70°C for 1 hr) prior to electrophoresis, binding 
of hemoglobin to skeletal proteins was reversed (Fig. 4.5). This observation indicated that 
hemoglobin was bound covalently to skeletal protein sulfhydryl groups through 
intermolecular disulfide bonds. 
Effect of 5-HPQ on the formation of Hb-membrane adducts in GSH-depleted RBCs. 
In order to further assess that the formation of Hb-adducts plays a direct role in the 
removal 5-HPQ-damaged red cells, we examined the formation of Hb-cytoskeletal 
protein adducts in red cells that were treated with sub-hemolytic concentrations of 5-HPQ 
that have been shown to be hemolytic to GSH-depleted red cells (Bowman et aI., 2004). 
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Fig. 4.4. Effect of 5-HPQ on rat erythrocyte membrane skeletal proteins. Red cells were 
incubated with vehicle (lane 1), 10 pM (lane 2), 25 pM (lane 3), 50 JlM (lane 4), 75 pM 
(lane 5) and 100 JlM (lane 6) 5-HPQ for 2 hr at 37°C. The cells were washed, and ghosts 
were prepared and washed exhaustively to remove unbound hemoglobin (Hb). The ghosts 
were then solubilized in SDS and subjected to PAGE. (A) Gel Code Blue-stained gel and 
densitometric scans; (B) immunoblot stained with polyclonal antibodies to rat 
hemoglobin. Molecular weight markers appear along the right side of the gel; the major 
cytoskeletal proteins are identified along the left side of the gel according to (Fairbanks et 
aI. , 1971). 
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Fig. 4.5. Effect of DTT on 5-HPQ-induced hemoglobin binding to membrane skeletal 
proteins. Erythrocytes were incubated with 5-HPQ for 2 hr at 37°C. Ghosts were 
prepared, washed exhaustively to remove unbound hemoglobin, and each sample was 
divided into two aliquots. Prior to electrophoresis, one aliquot was incubated with water 
and the other with 40 mM DTT for 1 hr at 70°C. The samples were then subjected to 
SDS-PAGE and blotted onto PVDF membranes. (A) Immunoblot stained with polyclonal 
antibodies to rat hemoglobin. Vehicle control (lanes 1 and 5), 25 JlM (lanes 2 and 6), 50 
}tM (lanes 3 and 7) and 75 JlM (lanes 4 and 8) 5-HPQ. (B) Selected densitometric scans. 
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Red cell aSH was depleted by >95% with DEM prior to treatment with 5-HPQ for 2 h at 
37°C. The range of 5-HPQ concentrations (2.5-25 pM) was chosen, since it was 
previously shown to span the red-cell survival concentration-response curve generated 
with GSH -depleted red cells treated in vitro were administered to rats in vivo (Bowman et 
aI.,2004). After treatment with 5-HPQ, membrane ghosts were prepared with hypotonic 
phosphate buffer and washed extensively to remove unbound hemoglobin. Ghost protein 
(15jlg) was then separated by SDS-PAGE, blotted to PVDF membranes, and 
immunostained with anti-rat hemoglobin antibodies. Immunoblot analysis showed 
enhanced binding of hemoglobin at concentrations as low as 2.5jlM 5-HPQ (Fig. 4.6). 
Significantly, the sharp, threshold-like response seen in GSH-normal cells (Fig. 4.4B) 
was lost and the TCso markedly reduced -5-fold, from 25-50jlM to approximately 5 ... 
10 pM. This data demonstrate that there is a strong correlation between the formation of 
Hb-adducts with the hemolytic activity previously observed in vivo for both GSH-normal 
and GSH-depleted red cells, indicating that the formation of disulfide-linked Hb-adducts 
with skeletal membrane proteins likely underlies the mechanism for the recognition and 
removal of 5-HPQ-treated red cells by splenic macrophages. 
Effect of DTT on 5-HPQ-induced Hb-adductformation and hemolytic susceptibility. 
While the correlation between the formation of Hb-cytoskeletal protein adducts and 
hemolytic activity is very strong, it was necessary to determine directly whether adduct 
formation is functionally significant for macrophage recognition and phagocytosis of 
damaged erythrocytes. We examined whether the reduction of Hb with DTT in intact 
cells could restore normal cytoskeletal protein sulfhydryl status to, in effect, "rescue" 5-
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Fig. 4.6. Effect of 5-HPQ on Hb-cytoskeletal protein adduct formation in GSH -depleted 
rat erythrocytes. GSH depleted (>95%) rat erythrocytes were incubated in the presence 
of vehicle (lane 1), 2.5}lM 5-HPQ (lane 2), 5}lM 5-HPQ (lane 3), lOflM 5-HPQ (lane 4), 
or 25}lM 5-HPQ (lane 5) for 2 hr at 37°C. Following exposure, the cells were washed 
and membrane ghosts were prepared and washed extensively to remove any unbound 
hemoglobin. The ghosts (15 }lg of protein) were subjected to SDS-PAGE, blotted onto 
PVDF membrane, and stained with antibodies against rat hemoglobin. The densitometric 
tracings of the blot (left) are shown on the right. 
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HPQ-damaged red cells from their phagocytic fate. The ability of OTT (5mM) to reduce 
the disulfide-linked Hb-adducts, which formed during incubation with 5-HPQ was 
examined. Red cells were treated with a 50pM 5-HPQ in the absence of DTT for 15 min, 
washed once with PBSG, and then treated with 5 mM OTT for 1 hr. The cells were once 
again was with PBSG and red cell membrane ghosts were prepared and washed 
extensively. The ghost protein (15pg) was then subjected to SDS-PAGE and Western 
blot using anti-rat hemoglobin antibodies. As shown in Fig. 4.7, the amount of 
membrane bound Hb was markedly reduced in cells treated with OTT. 
Next, we determined whether this reduction of Hb from cytoskeletal membrane 
proteins demonstrated any functional significance, i.e. whether OTT could "rescue" 5-
HPQ-damaged erythrocytes. 51Cr-Iabeld red cells were treated in vitro with 50pM 5-HPQ 
for either 20 or 40 min, washed once with PBSG, then treated with or without 5mM OTT 
for 1 hr. As shown in Fig. 4.8, administration of these erythrocytes to rats showed that 
OTT effectively "rescued" red cells treated with 5-HPQ for 20 min but not 40 min, 
suggesting that the red cells were committed to their fate by 40 min. This time-dependent 
commitment supports the concept that the appearance of an extracellular cell-surface 
signal is dependent on an inside-out signal transduction, from the intracellular membrane 
surface across the membrane to the extracellular cell surface. 
Discussion 
It is well recognized that primaquine administration can cause oxidative damage to 
erythrocytes, resulting in methemoglobinemia and hemolytic anemia. At 
pharmacologically relevant concentrations, primaquine is not directly toxic to red cells; 
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Fig. 4.7. Effect of OTT on 5-HPQ-induced Hb-cytoskeletal protein adducts in intact rat 
erythrocytes. Red cells were incubated with vehicle (lane 1) or 50}lM 5-HPQ (lane 2 and 
lane 3) for 15 min at 37°C, then washed once with PBSG and treated with vehicle (lane 1 
and lane 2) or 5 mM OTT (lane 3) for 1 hr at 37°C. After incubation, the cells were 
washed once more with PBSG, and ghosts were prepared and washed extensively to 
remove unbound Hb. The ghosts (15}lg of protein) were then subjected to SDS-PAGE, 
blotted onto a PVOF membrane, and stained with antibodies to rat Hb. Densitometric 
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Fig. 4.8. Effect of DTT on the survival of rat 51Cr-labeled erythrocytes in vivo after in 
vitro exposure to 5-HPQ (50jlM) for (A) 20 min or (B) 40 min ° The red cells were 
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and administered intravenously to isologous rats. To blood samples were taken 35 min 
after administration of labeled cells. Data points are means ± SD (n = 4). 
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the toxicity is thought to be due to redox-active metabolites that generate ROS. When 
formed in sufficient quantity and rate, these ROS are considered to overwhelm cellular 
defenses and attack various protein andlor lipid components of the red cell. By 
identifying the toxic metabolite(s) and understanding the mechanism underlying the 
hemolytic response, it may be possible to undertake a rational redesign of the primaquine 
molecule to reduce toxicity while maintaining anti-malarial efficacy. 
Previous studies have shown that the phenolic metabolite, 5-HPQ, has the capacity to 
redox cycle and generate ROS, and they suggested that it could contribute to the 
hemotoxicity of the parent drug (Vasquez-Vivar and Augusto, 1992). We have recently 
confirmed the hemolytic potential of 5-HPQ by demonstrating that it is a direct-acting 
hemolytic agent in the rat (Bowman et aI., 2004). In these studies, slCr-tagged 
erythrocytes were treated with 5-HPQ in vitro and then re-administered to isologous rats. 
The treated cells were rapidly removed from the circulation of the rats as compared with 
saline-treated controls. The concentration-dependence of this response was sharp, with a 
minimum response at 25 pM 5-HPQ, an ECso at about 40 JiM, and a maximal response at 
75 JiM. In addition, hemolytic activity was strongly correlated with depletion of aSH and 
formation of glutathione-protein mixed disulfides. These observations were similar to the 
pattern of oxidative stress-induced damage observed previously in red cells exposed to 
other direct-acting, pro-oxidant hemolytic agents, such as dapsone hydroxylamine 
(Bradshaw et aI., 1997). However, the precise intracellular molecular targets of oxidative 
damage have not been identified, nor has the mechanism whereby internal oxidative 
damage is translated to an external cell-surface marker that enables splenic macrophages 
to recognize and remove the damaged red cells. 
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Since mature red cells lack nuclei and other organelles, the lipid and protein of the 
plasma membrane appear to be the most likely targets of intracellular ROS. In regard to 
lipids, it is well known that they are prime targets for ROS-initiated lipid peroxidation, 
which is thought to result in membrane blebbing and frank cell lysis. In addition, 
oxidative stress has been shown to alter the asymmetric distribution of phospholipids 
within the bilayer (Jain, 1984). A functional role for this asymmetry was demonstrated 
when it was shown that phosphatidylserine translocation to the outer leaflet resulted in an 
increased susceptibility of erythrocytes to phagocytosis by macrophages (Zwaal and 
Schroit, 1997). 
More recently, studies on the normal, physiological removal of senescent erythrocytes 
have suggested that senescent erythrocytes undergo a process that is analogous to the 
apoptotic program observed in other cell types. For example, treatment of human red 
cells with t-butylhydroperoxide was shown to stimulate caspase 3 activation and 
phosphatidylserine extemalization (MandaI et aI., 2002). Additional studies have shown 
that peroxidation of phosphatidy lserine in cells undergoing apoptosis causes a reduced 
affinity of aminophospholipid translocase for the oxidized phospholipid, resulting in the 
accumulation of phosphatidylserine in the outer leaflet (Tyurina et aI., 2000). On the 
other hand, other investigators have found no association between oxidative stress and 
loss of phospholipid asymmetry in human erythrocytes (de long et aI., 1997). 
An alternate hypothesis is that erythrocyte proteins are critical targets of intracellular 
ROS. Previous studies have shown that hemoglobin and proteins of the membrane 
cytoskeleton are altered in response to pro-oxidant hemolytic agents, and this is reflected 
by the generation of reactive forms of hemoglobin, such as ferryl heme (Bolchoz et aI., 
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2002a) and hemoglobin thiyl free radicals (Bradshaw et aI., 1995), and by changes in the 
normal electrophoretic pattern of skeletal proteins on non-reducing SDS-PAGE gels 
(Grossman et aI., 1992; McMillan et aI., 1995; McMillan et aI., 2001). Evidence for the 
functional importance of normal protein-protein interactions among cytoskeletal, integral 
membrane and external cell surface proteins was illustrated by recent studies showing 
that these interactions are necessary to confer the recognition of "self' to circulating 
erythrocytes (Oldenborg et aI., 2000; Bruce et aI., 2002). 
The studies presented in this chapter were undertaken to determine the effect of the 
redox-active primaquine metabolite, 5-HPQ, on generation of ROS in red cells and on the 
consequences of ROS generation to erythrocyte membrane lipids and proteins. Given the 
association between 5-HPQ-induced oxidative stress and its hemolytic activity, we 
analyzed rat red cell lipids for peroxidation and loss of phosphatidylserine asymmetry, 
and skeletal proteins for electrophoretic alterations and hemoglobin binding under 
experimental conditions associated with the generation of intracellular ROS. 
DCFDA is a fluorescence-based probe that has been developed to detect intracellular 
production of ROS. DCFDA diffuses passively into cells where it is deacetylated to form 
2' ,7' -dichlorodihydrofluorescein. 2',7' -Dichlorodihydrofluorescein is then converted to a 
fluorescent product, 2' ,7' -dichlorofluorescein, by ROS, thus providing a general 
assessment of intracellular oxidative stress (Hempel et aI., 1999; Halliwell and 
Whiteman, 2004). The data presented in Fig. 4.1 show a concentration-dependent 
increase in DCFDA oxidation in rat erythrocytes treated with 5-HPQ, indicating that 
ROS formation is associated with the hemolytic response in both a concentration- and 
time-dependent manner. DCFDA oxidation continued for at least 20 min, which is of 
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interest because 5-HPQ has an extremely short half-life «1 min) in erythrocyte 
suspensions (Bowman et aI., 2004). Although the reason for this relatively long 
generation of ROS relative to 5-HPQ stability is not understood, it raises the intriguing 
possibility that some as yet unknown reactive intermediate with a longer half-life is 
generated in red cells under hemolytic conditions. 
To assess whether lipid peroxidation was associated with 5-HPQ-induced hemolytic 
injury, the formation of F2-isoprostanes was quantified in erythrocyte ghosts by GC-MS. 
Treatment with a range of concentrations of 5-HPQ, from sub-hemolytic (10 pM) to 
maximally hemolytic (70 pM), did not reveal any increase in the content of F2-
isoprostanes in 5-HPQ-treated erythrocytes as compared to the control (Fig. 4.2). In 
agreement with the lipid peroxidation data, analysis of phosphatidy lserine extemalization 
(Fig. 4.3) supported the concept that erythrocyte membrane lipids are not targets of 5-
HPQ-generated ROS, and suggest that phosphatidylserine exposure on the external cell 
surface does not occur and thus is not a signal for uptake of 5-HPQ-treated red cells into 
the spleen. 
In contrast to membrane lipids, exposure to 5-HPQ caused profound alterations to the 
red cell protein cytoskeleton (Fig. 4.4A). Of importance, the concentration dependence 
for this effect coincided with that of 5-HPQ-induced hemolytic activity. Gel Code Blue 
staining of ghost proteins resolved by SDS-PAGE showed alterations to several proteins, 
including the loss of resolution and/or splitting of protein bands in the spectrin/ankyrin 
region, loss of band 4.2, and the appearance of membrane-bound hemoglobin. 
Disappearance of band 4.2 was perhaps the most interesting effect. Band 4.2 has been 
shown to be a member of the band 3 complex, which includes band 3 (anion exchanger 
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1), band 2.1 (ankyrin) and CD47 (Bruce et ai., 2003). Band 3 is an integral membrane 
protein that is anchored to the underlying cytoskeleton through its interaction with 
ankyrin. The extracellular domain of CD47 has been shown to act as a ligand for the 
inhibitory signal regulatory protein alpha (SIRPa) on splenic macrophages (Oldenborg et 
aI., 2001). As noted above, this interaction is thought to confer self-recognition to normal 
red cells, preventing their phagocytic removal (Oldenborg et aI., 2000). These findings 
are of relevance to the hemolytic response because other studies have shown that band 
4.2 forms a vertical association between CD47 and ankyrin, thereby mediating cell-
surface expression of CD47 and its membrane skeleton attachment in human erythrocytes 
(Dahl et aI., 2004). While the fates of band 4.2 and ankyrin are not clear from these 
experiments, immunoblotting with anti-rat hemoglobin showed that significant amounts 
of hemoglobin are bound to mUltiple proteins of the band 3 complex (Fig. 4.4B). The 
pattern of Hb-binding correlated very strongly with the concentration-responses for the 
hemolytic activity of 5-HPQ in both aSH-normal (Fig. 4.4B) and aSH-depleted red cells 
(Fig. 4.6), indicating a direct role for the formation of Hb-cytoskeletal protein-adducts in 
the removal of 5-HPQ-damaged erythrocytes. Treatment of erythrocyte ghosts with the 
disulfide-reducing agent, DTT, showed that covalent binding of hemoglobin to these 
proteins occurred through the formation of intermolecular disulfide bonds (Fig. 4.5), and 
treatment of intact erythrocytes with DTT indicated that the covalent binding of 
hemoglobin could be reversed in the intact, viable cell (Fig. 4.7). In order to determine 
whether the reduction of 5-HPQ-induced Hb-adducts by DTT in whole cells showed any 
functional significance, we examined the hemolytic removal of 51Cr-Iabeled, 5-HPQ-
treated, DTT -"rescued" erythrocytes in vivo and found that these cells were "rescued" 
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after 20 min of treatment with 50}tM 5-HPQ compared to controls not receiving DTT 
(Fig. 4.8A). Treatment with DTT reduced the fractional removal at 48 hrs of damaged 
red cells exposed to 5-HPQ for 20 min by ,.w35%. However, exposure to 5-HPQ for 40 
min followed by treatment with DTT only reduced the fractional removal by ,.w5%, 
indicating that by 40 min virtually all of 5-HPQ-damaged red cells are committed to their 
fate. It is conceivable that intracellular damage by 40 min has been translated into an 
external cell surface signal that is no longer responsive to reduction by DTT. 
When taken into consideration with previous studies, these results indicate that redox 
cycling of 5-HPQ causes enhanced ROS formation (Fig. 4.9), which overcomes 
antioxidant defenses. Hemoglobin, which is in close proximity to ROS generation, is a 
preferential target. Attack of ROS on hemoglobin may result in the formation of 
hemoglobin thiyl radicals (Bradshaw et aI., 1995) and/or ferryl heme species (Bolchoz et 
at, 2002a), which are highly reactive but which lack the lipophilicity to penetrate into the 
membrane to initiate lipid peroxidation. Instead, these putative thiyl radicals could react 
with sulfhydryl-groups on a variety of structural proteins to form hemoglobin adducts 
(Jollow and McMillan, 2001). Given our previous observations of the formation of 
glutathione-protein mixed disulfides (Bowman et at, 2004) and our current observation 
of disulfide-linked hemoglobin-skeletal proteins (Figs. 4.5, 4.6, 4.7, and 4.8), it seems 
reasonable to hypothesize that 5-HPQ may be operating in a similar fashion. Additional 
studies will be necessary to determine whether thiyl radicals or other reactive species can 
be detected in response to treatment with 5-HPQ. Additional studies are also warranted 
to determine the precise protein targets of hemoglobin adduct formation that lead to 
splenic sequestration; however, it is not inconceivable to predict that binding of 
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hemoglobin monomers to proteins of the band 3 complex would lead to profound 
functional disturbances in cytoskeletal protein-protein interactions that are transmitted to 
the external surface of the erythrocyte, providing a signal for macrophage recognition. 
In summary, we have shown that a hemolytic metabolite of primaquine, 5-HPQ, does 
not cause lipid peroxidation or loss of phosphatidylserine asymmetry despite the 
generation of ROS. Thus, lipids do not appear to be targets during the course of oxidative 
damage to 5-HPQ-treated rat erythrocytes, Rather, the data are consistent with the 
concept that cytoskeletal protein damage, in the form of disulfide-linked hemoglobin 
adducts, underlies the process of recognition and removal of 5-HPQ damaged 
erythrocytes, Additional studies are warranted to elucidate the process that underlies the 
loss of self-recognition. 
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Fig. 4.9. Working hypothesis for the mechanism underlying the hemolytic activity of 5-
HPQ in rat erythrocytes. See text for description. 
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Summary, Discussion and Future Directions 
Hemolytic anemia was first recognized as a toxic side effect of pamaquine in 1926 
(Cordes, 1926). Since that time, a wide variety of drugs and environmental chemicals 
have also been shown to elicit this toxic effect as well. As early as 1959, several 
observations from studies on the toxicity of primaquine supported the conclusion that 
hemolytic drugs cause the accelerated removal of red cells from the circulation by 
inflicting oxidative damage. Evidence for this included the following characteristic 
observations: 1) the depletion of cellular reduced glutathione, 2) oxidation of hemoglobin 
to methemoglobin, and 3) that "primaquine-sensitive" individuals also possessed an 
intrinsic red cell deficiency of glucose-6-phosphate dehydrogenase (Beutler, 1959). 
The mechanisms of red cell sequestration for both hemolytic anemia and 
physiological erythrocyte senescence are thought to share the involvement of intracellular 
oxidative stress and uptake of damaged red cells by the spleen. This commonality has led 
to the hypothesis that both processes might operate through similar mechanisms, such 
that the mechanism of hemolytic anemia could result from an acceleration of the normal 
red cell senescence mechanism. Studies on the cellular and molecular mechanisms of 
senescent erythrophagocytosis have provided "numerous, and often conflicting, 
hypotheses" to address the question of "what is the critical signal that it, and it alone, will 
activate the resident macrophage to adhere to and engulf [the senescent red cell]" 
(Bratosin et aI., 1998). A collection of studies has shown that the primary signal could 
either be protein, carbohydrate, or lipid in nature, and to potentially result from either the 
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unmasking of a "senescent cell antigen" (Kay, 1994) or from spatial remodeling of 
membrane proteins that are then either recognized by macrophages via opsonization by 
circulating "senescent antibodies" or by macrophage receptors directly. The only 
certainty is that a great deal of controversy remains with respect to the mechanisms of red 
cell senescence and hemolytic anemia. 
Very early on, primaquine-induced oxidative damage was recognized to be mediated 
by redox active "metabolic products" rather than the parent drug itself (Earle et aI., 
1948). Studies have shown that the N -hydroxy metabolites of certain arylamine 
compounds, such as aniline and dapsone, are able to mediate the hemolytic activity of the 
parent compounds (Harrison and Jollow, 1986; Grossman and Jollow, 1988). Thus, in 
order to investigate whether an arylhydroxylamine metabolite contributed to the overall 
hemotoxicity of primaquine, the toxicity of the N-hydroxy type metabolite, MAQ-NOH, 
was recently examined in our laboratory. Laura Bolchoz demonstrated that MAQ-NOH 
could be formed by N-oxidation of 6-MAQ, an N-dealkylated primaquine metabolite that 
has been shown to be formed in humans (Bolchoz et aI., 2001), and was a direct-acting 
methemoglobinemic and hemolytic agent in rats. She postulated that it induced its 
hemolytic injury via the generation of intracellular ROS, which oxidized lipids in GSH-
normal rat erythrocytes and oxidized proteins GSH-depleted red cells. The results of her 
studies led to the conclusion that MAQ-NOH had the requisite properties to significantly 
contribute to the overall hemotoxicity of primaquine. However, neither the relative 
contribution of MAQ-NOH nor the potential contributions of other types of metabolites 
were assessed. 
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In 1962, Tarlov et al. suggested that the phenolic metabolites of primaquine were 
likely to play an important role in its hemotoxicity (Tarlov et aI., 1962). However, 
experimental support for this hypothesis did not appear until the mid-1980s, when 
identification of phenolic metabolites in animals and synthesis of test compounds by the 
U.S Army Drug Development Program made research possible. Results from those 
studies demonstrated that in vitro incubation of red cells with the phenolic metabolites, 5-
HPQ and 5,6-DHPQ, produced a number of oxidative effects, including: 1) the depletion 
of cellular reduced glutathione (Agarwal et aI., 1988; Fletcher et aI., 1988), 2) oxidation 
of hemoglobin to methemoglobin (Agarwal et al., 1988; Fletcher et al., 1988), and 3) 
stimulation of HMP shunt activity (Baird et al., 1986). Collectively, these data led to the 
postulate that quinoneimine and/or quinone metabolites of primaquine could redox cycle 
and thereby generate toxic levels of reactive oxygen species, which damage cellular 
components and lead to the accelerated removal of damaged cells from the circulation. 
However, direct evidence linking the biochemical changes observed in vitro to the 
hemolytic activity in vivo was lacking. Likewise data regarding the possible targets of 
oxidative damage, which would have illuminated the precise mechanism(s) by which 
metabolite-induced oxidative stress leads to the recognition and removal of damaged 
erythrocytes from the circulation, was also not available. Currently, any progress towards 
understanding the role of phenolic metabolites in primaquine-induced hemolytic anemia 
is hampered because the compounds are no longer available, the synthetic methods to 
prepare them are relatively difficult, and the products are very unstable. 
The purpose of this dissertation was to examine the hemolytic potential of the 
quinoneimine-type phenolic metabolite, 5-hydroxyprimaquine, and our experimental 
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approach was as follows: 1) to synthesize 5-HPQ, characterize its chemical properties in 
order to learn how to properly handle and deliver the compound to experimental models; 
2) to use an in vitro exposure/in vivo survival model to establish the direct hemolytic 
activity of 5-HPQ; 3) to characterize the pattern of 5-HPQ-induced oxidative stress 
within the red cell in vitro under toxicologically relevant conditions; 4) to examine 
possible membrane targets of oxidative damage; and 5) to determine a role for splenic 
macrophages in the hemolytic removal of 5-HPQ-damaged red cells. The data presented 
in this dissertation has provided evidence for the likely contribution of 5-HPQ to the 
overall hemotoxicity of primaquine, as well as significant insight into the mechanism of 
red cell removal in drug-induced hemolytic anemias and normal red cell senescence. 
Synthesis and characterization of 5-HPQ, a quinoneimine-type metabolite 
5-HPQ is no longer available from any source, commercial or otherwise. Thus, as a 
first step in our investigation, we re-synthesized 5-HPQ (Allahyari et aI., 1984) and 
examined its chemical properties, including its stability and ability to redox cycle. The 
chemical instability of 5-HPQ in both aqueous solution and in the crystal state has been 
previously reported (Link et aI., 1985), so in order to be confident that 5-HPQ was 
delivered to our experimental models intact, it was necessary to quantify this instability 
(Fig. 2.5). In agreement with the previous studies, we found that 5-HPQ was extremely 
unstable in blood and aerated buffer at physiological pH, and we determined that this 
instability was due to complete degradation of the redox pair and not merely a product of 
oxidation to the quinoneimine. 
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It was necessary then, given its instability, to develop a method that would allow us to 
reliably deliver 5-HPQ to red cell suspensions intact and in known concentrations. The 
observation that direct synthetic precursor of 5-HPQ, 5-methoxyprimaquine (Fig. 2.2) 
was stable and could be stored for extended periods of time allowed us to avoid 
significant degradation by freshly preparing 5-HPQ from its stable precursor as needed. 
Additionally, the NMR studies that were performed to initially characterize 5-HPQ 
showed that it would remain stable for over 24 hours when maintained at a low pH and 
under strictly anaerobic conditions, and thus provided us with a method to deliver 5-HPQ 
to experimental models. The high degree of reproducibility that was observed from one 
experiment to the next, e.g. the similar hemolytic response observed in three separate 
experiments, demonstrated our ability to reliably deliver 5-HPQ (Figs. 2.7,3.1, and 4.8). 
Thus, despite the rapid degradation of 5-HPQ upon addition to red cell suspensions, we 
could be confident that we delivered 5-HPQ intact and in the appropriate concentrations. 
Formation of 5-HPQ-induced ROS 
5-HPQ caused a significant, concentration-dependent increase in ROS generation in 
red cells, which continued unabated for at least 20 min (Fig. 4.1), despite a very short 
half-life of 5-HPQ in the blood (Fig. 2.5). The observation that DCFDA oxidation in rat 
erythrocytes increases following treatment with concentrations of 5-HPQ that were 
shown to be hemolytic, indicates that the formation of ROS was associated with the 
hemolytic response. However, the finding that ROS formation was detected well after 5-
HPQ was degraded raises the likelihood of some as yet unknown reactive intermediate 
with a longer half-life that mediates 5-HPQ-induced hemotoxicity. 
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Fig. 5.1. Schematic representation of 5-HPQ autooxidation: (A) compound structures; 
(B) suggested reaction sequence (hydrogens and charges are not balanced to avoid 
changing the basic abbreviation used for 5-HPQ). 
(Vasquez-Vivar and Augusto, 1990) 
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DCFDA is a non-fluorescent compound that is converted by reactive species into the 
fluorescent compound, DCF, and thus provides a valuable assay that can be utilized for 
the detection of free radical species. The DCFDA assay is able to detect the formation of 
peroxyl (R02e), alkoxyl (ROe), N02e, C03e-, ONOO-, and OHe radicals, but not H20 2 or 
superoxide directly (Halliwell and Whiteman, 2004). It should be noted that this list is 
not definitive for the specificity of the assay, and it could be that a one-electron oxidation 
of DCFH by a wide variety of free radicals and heme proteins (i.e. hemoglobin) might 
also produce a positive result (Halliwell and Whiteman, 2004). Thus, while it is 
reasonable to conclude that 5-HPQ generates the formation of reactive species in red cells 
in general, no definitive statement with respect to the specific species formed can be 
made based on this data (Fig. 4.1). Future experiments could be conducted using EPR 
spectroscopy and appropriate spin-trapping techniques to identify the specific free 
radicals present in red cell suspensions exposed to hemolytic concentrations of 5-HPQ. 
Initial studies utilizing oxygen consumption and spin-trapping EPR led to the 
postulate that 5-HPQ has the capacity to redox-cycle and thereby generate H20 2, 
hydroxyl radicals, and a semiquinoneimine intermediate in aerated buffer according the 
schematic depicted in Fig. 5.1 (Vasquez-Vivar and Augusto, 1990; Vasquez-Vivar and 
Augusto, 1992). To confirm whether 5-HPQ could reversibly cycle, we examined its 
electrochemical activity in argon-purged PBSG (pH 7.4) using cyclic voltammetry (Fig. 
2.6) and made observations that were consistent with the concept that 5-HPQ could 
undergo cycling as a fully reversible redox couple via a semiquinone radical intermediate 
at physiological pH. 
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It is well known that H20 2 reacts with hemoglobin to form ferryl-heme, and thus 
ferryl-heme levels in the red cell can reflect the formation of H20 2 in excess of its 
metabolic clearance (Harel and Kanner, 1988). Additionally, ferryl-heme itself is thought 
to be a strong cytotoxic oxidizing agent that is capable of peroxidation of unsaturated 
fatty acids (Kanner and Harel, 1985). To examine whether ferryl-hemoglobin, and by 
extension H20 2, were formed in red cells following exposure to hemolytic concentrations 
of 5-HPQ, we utilized a spectrophotometric scanning technique that can detect ferryl-
hemoglobin formation in red cells (Bolchoz et aI., 2002a). However, Fig. 5.2 shows that 
we could not detect any significant formation of H20 2 relative to controls. It should be 
noted that this assay does not allow us to specifically rule out the formation of H20 2, but 
it does suggest that, if formed, it does not react with hemoglobin. And at a minimum, 
ferrylhemoglobin does not appear to contribute significantly to 5-HPQ-induced 
hemotoxicity. 
When discussing reactive species, it must be understood, that species such as H20 2 
and hydroxyl radical are extremely reactive and short-lived, and are not able to account 
for the prolonged generation of ROS that we observed. Likewise, the rapid degradation of 
the 5-HPQ redox pair necessitates rapid degradation of any semiquinoneimine or other 
compound-centered free radical. Thus future studies are necessary to examine the identity 
or identities of longer-lasting intermediate reactive species. One attractive possibility is 
the potential involvemnt of reactive sulfur species (RSS), which have been recently been 
suggested to play a role in oxidative stress and to present an interesting possibility for 
longer-lasting reactive intermediate (Giles et aI., 2001). Free thiol-groups are known to 
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Fig. 5.2. The time-dependent, spectrophotometric detection of 5-HPQ-induced ferryl-
hemoglobin formation. Rat erythrocytes (40% suspension) were pre-incubated with 
sodium sulfide (2 mM), which traps ferryl-heme species as sulfhemoglobin (Amax 620 
nm). Potassium cyanide (10%, 20 }II) was also added to remove any interference from 
methemoglobin (Amax 620 nm). Values for control and 5-HPQ samples are means ± S.D. 
(n = 3). Values for MAQ-NOH samples represent an n of 1. 
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It has recently been shown that the disulfide can be further oxidized to either a disulfide-
S-monoxide or a disulfide-S-dioxide under conditions of oxidative stress (Fig. 5.3). The 
sulfur atom in these molecules resides in a higher than normal oxidation state, which 
increases the reactivity of the disulfide toward other thiols via a sulfur-sulfur exchange 
reaction. As shown in Fig. 5.3, formation of protein mixed-disulfides by either the 
disulfide-S-monoxide or the disulfide-S-dioxide can also result in the production of 
sulfenic and sulfinic acid, which themselves are also strong oxidizing agents (Giles et aI., 
2001). Importantly, RSS are formed with relative ease under physiological conditions of 
oxidative stress, which underlies their potential to enhance oxidative stress in vivo. 
Although limited information is available regarding the formation of RSS, they do 
represent an intriguing possibility for an intermediate that might mediate a sustained 
oxidative stress long after the decay of 5-HPQ. 
Hemolytic concentration-response relationship 
Having synthesized 5-HPQ and developed a method to deliver it intact to red cell 
suspensions, our next step was to determine whether 5-HPQ could act as a direct acting 
hemolytic agent. To this end, we used an in vitro exposure/ in vivo survival model that 
has been previously developed and characterized by our laboratory (Harrison and Jollow, 
1986). Specifically, slCr-labeled rat erythrocyte suspensions were exposed to various 
concentrations of 5-HPQ in vitro for 2 hr at 37°C, and then cells were washed and 
returned to the circulation of isologous rats. Serial blood samples were taken at specific 
intervals, and loss of radioactivity from the circulation over time was measured as 
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Fig. 5.3. Oxidative formation of disulfide-S-oxide RSS and subsequent sulfur-sulfur 
exchange to form the mixed disulfide. The disulfide B is formed from thiol A under 
oxidative conditions [0]. Further oxidation of the disulfide moiety yields either the 
disulfide-S-monoxide C or the disulfide-S-dioxide D. Activation of the disulfide via 
sulfur oxidation renders the bond more labile and promotes the reaction with a reduced 
thiol to form the mixed disulfide E and the sulfenic or sulfinic acid. 
(Giles et aI., 2001) 
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evidence of direct hemolytic activity. Importantly, it should be noted that the 
concentrations of 5-HPQ used in this model are not predictive of what would be required 
in vivo, but rather, this model permits the comparison of the relative potencies of a 
variety of direct-acting hemolytic agents. Additionally, specific cellular biochemical 
alterations can be directly correlated with the hemolytic removal from the circulation in 
vivo following the same in vitro treatment conditions. The data obtained from this model 
demonstrated that 5-HPQ is the most potent direct hemolytic agent that we have 
examined to date. Additionally, we were able to show that the direct hemolytic activity 
was dependent on intracellular levels of GSH and binding of Hb to membrane proteins. 
It should also be noted that the cellular injury that results from drug-induced 
oxidative damage has been shown to be time-dependent (Grossman and Jollow, 1988; 
McMillan et aI., 1991), which suggests that hemolytic injury is cumulative in nature 
rather than proportional to drug concentration. That is, the severity of hemolytic damage 
can be thought of as a series of "hits" on cellular targets that accumulate over time, rather 
than as a reversible drug-receptor association that is dependent on drug concentration. 
For example, 3,4-dichlorophenylhydroxylamine-treated red cells were shown to elicit a 
hemolytic response that was not found to correlate the peak plasma concentration, but 
with the area under the blood concentration versus time curve (McMillan et al., 1991). 
Additionally, primaquine has a high bioavailability (>75%), a significant half-life (--7 
hours), an extensive metabolism (renal elimination of <1 % of the parent compound), and 
is chronically administered, thus it is conceivable that the AVe for 5-HPQ could be 
significant. Furthermore, if the toxicity of 5-HPQ is due to the accumulation of "hits" on 
red cells, the reactivity of 5-HPQ could cause damage to accumulate, despite a low or 
135 
undetectable peak plasma concentration at any given time. As a compromise between 
achieving a drug-AUe necessary to elicit a hemolytic response and the necessity to return 
cells to the circulation relatively quickly in order to maintain control-cell viability, we 
have chosen an incubation time of 2 hours for the in vitro exposure to hemolytic agents. 
In theory, a similar hemolytic response would be observed if lower concentrations of 5-
HPQ were used and the treatment time increased, but the maintenance of control red cell 
viability decreases with longer incubation times. However, if a specific incubation time is 
chosen (Le. 2 hours) and used consistently from one experiment to the other, the relative 
potency of a variety of toxic compounds can be assessed. 
One additional point to be considered is that the hemolytic assay is generally 
performed using G6PD-normal rat erythrocytes. These cells have normal GSH levels 
and normal antioxidant enzyme activity when challenged by drug-induced oxidative 
stress, and thus the concentrations used must be able to overwhelm normal antioxidant 
defenses before eliciting a toxic response. Importantly, when GSH was depleted in red 
cells by >95% with diethyl maleate in order to mimic in vitro the GSH instability 
observed in G6PD-deficient red cells in vivo, the hemolytic response observed with 5-
HPQ was markedly enhanced and an effect was observed with as little as 1-2JlM 
following the relatively brief 2 hour incubation period. 
Role ofGSH in 5-HPQ-induced hemolytic anemia 
Previous studies with 5-HPQ have shown that it causes an extensive depletion of 
GSH in isolated suspensions of rat and human erythrocytes (Allahyari et aI., 1984; 
Agarwal et aI., 1988; Fletcher et aI., 1988). We demonstrated that the concentration-
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dependence for 5-HPQ-induced aSH-depletion was sharp, exhibiting a threshold-like 
response (Fig. 2.9) that coincided with the concentration-dependence for the formation of 
mixed disulfides between GSH and soluble red cell protein (Fig. 2.9A). Furthermore, the 
concentration-response curve for aSH-depletion was found to closely coincide with the 
concentration-response curve for the hemolytic activity (Fig. 2.7). Additionally, 
depletion of GSH with DEM in red cells in vitro prior to 5-HPQ-exposure markedly 
enhanced the hemolytic response with a loss of the apparent threshold (Fig. 2.10). 
Collectively, these data strongly supported the concept that the hemolytic response 
induced by 5-HPQ had a discrete dose threshold and that this threshold was dependent on 
the presence of aSH in the red cell. 
In view of the involvement of aSH in 5-HPQ-induced hemotoxicity, it is reasonable 
to speculate as to its specific role. Evidence exists that rat erythrocytes produce large 
quantities of hemoglobin-GSH mixed disulfides when exposed to oxidative stress 
(Grossman and Jollow, 1988; Lii and Hung, 1997; Rossi et aI., 1998; Murakami and 
Mawatari, 2003). Given the significant production of these mixed disulfides, it is 
reasonable to conclude that 5-HPQ-induced depletion of GSH results primarily in the 
formation of Hb-GSH mixed disulfides (Fig. 2.9). Additionally, hemoglobin thiyl free 
radicals have been shown to be formed in red cells under oxidative-stress inducing 
conditions (Maples et aI., 1988; Maples et aI., 1990a; Maples et aI., 1990b; Bradshaw et 
aI., 1995), and although a thiyl radical has yet to be detected in red cells after exposure to 
5-HPQ, our results agree with the hypothesis that hemoglobin is activated to a thiyl free 
radical by a 5-HPQ-induced reactive species. Under this hypothesis, cellular reduced 
GSH would react with the newly formed thiyl radical to form a mixed disulfide, initially 
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stifling the toxic species and protecting the red cell. However, under our treatment 
conditions, aSH was rapidly and completely depleted, which allowed the hemoglobin 
thiy I free radicals to attack other cellular components. Additional studies are necessary to 
determine whether the formation of thiyl radicals can be detected by EPR in response to 
treatment of red cells with 5-HPQ. 
Cell membrane targets of 5-HPQ-induced oxidative damage 
It is clear that 5-HPQ-induced ROS formation results in an attack on the cytosolic 
surface of the plasma membrane that leads to a signal for removal of damaged 
erythrocytes from the circulation. In order to determine the nature of the crucial targets 
of oxidative damage, we addressed two possibilities: 1) that red cell damage is analogous 
to the apoptotic response observed in other nucleated cell types, which results in loss of 
the normal asymmetric distribution of phosphatidylserine in the cell membrane (MandaI 
et aI., 2002); and 2) that the oxidation of integral membrane proteins is involved in the 
link between internal oxidative stress and external recognition and removal of 
erythrocytes from the circulation. 
With respect to the first hypothesis, lipid peroxidation and PS externalization have 
been previously shown to occur from peroxide-induced oxidative stress (Jain, 1984; 
MandaI et aI., 2002). In order to determine whether these alterations occurred during the 
course of 5-HPQ-induced oxidative stress, we quantified lipid peroxidation by the direct 
measurement of free F2-isoprostanes (Fig. 4.2), and PS externalization by both the 
annexin labeling of erythrocytes and the PS-dependent prothrombinase assays (Fig. 4.3). 
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None of these assays demonstrated any significant effect on red cell membrane lipids 
following exposure to hemolytic concentrations of 5-HPQ. 
Given that we have shown the formation of reactive species that are capable of 
initiating lipid peroxidation, but that there was no lipid peroxidation, our data met some 
initial resistance with manuscript reviewers. However, we took special care to use the 
gold standard for the measurement of lipid peroxidation. Lipid peroxidation is a 
notoriously difficult response to measure, and the failure to detect it experimentally may 
not necessarily prove that it does not occur. Unfortunately, most of the commonly used 
methods that could be used to confirm its absence, such as the TBARS or conjugated-
dienes assays, are well-known to be non-specific and unreliable (Moore and Roberts, 
1998; Halliwell and Whiteman, 2004). Furthermore, it has been found that hydrogen 
peroxide-generating agents give rise to fluorescent pigments of hemoglobin, which have 
a maximum absorbance at 533 nm and thus interfere with the TBARS assay, which is 
read at 530 nm (i.e., give false positives). Other assays that have been used in our lab, 
including the fluorescent lipid probe, cis-paranaric acid, are also prone to artifacts and 
interference by the formation of methemog.lobin (McMillan et aI., 1998). For these 
reasons we utilized what is currently considered by most investigators in the field to be 
the "gold standard" for the quantification of lipid peroxidation, i.e. direct measurement of 
free F2-isoprostanes by Ge/Ms. Furthermore, since the products of lipid peroxidation are 
thought to result in PS translocation, results from the two separate assays that assessed PS 
extemalization, which were not influenced by fluorescent heme derivatives, confirmed 
the observed lack of lipid peroxidation. 
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The apparent contradiction between previously published results of oxidant induced 
lipid peroxidation and our own "controversial" data can be reconciled by considering the 
origin of oxidative stress. The high reactivity of hydroxyl radicals causes them to react in 
very close proximity to where they are formed. Previously, lipid alterations from 
oxidative stress were assessed following the addition of peroxides, such as H20 2, cumene 
hydroperoxide and t-butyl hydroperoxide to red cell suspensions. These reactive species 
encounter the membrane prior to any other cellular component and can be considered to 
cause an oxidative stress from the "outside-in". Alternatively, quinoneimine-, quinone-, 
or hydroxylamine-type compounds must first penetrate into the cytoplasm before they 
redox cycle and generate ROS from the "inside-out". Thus reactive species are more 
likely to react with cytoplasmic components in close proximity, i.e., hemoglobin, rather 
than membrane lipids. 
In agreement with this hypothesis, exposure to 5-HPQ was found to cause profound 
alterations to the red cell hemoglobin and the protein cytoskeleton, principally in the form 
of disulfide-linked hemoglobin adducts (Figs. 4.4, 4.5, 4.6 and 4.7). The concentration-
response for hemoglobin binding to skeletal membrane proteins correlated very strongly 
with the hemolytic response for aSH-normal cells, and when aSH was depleted with 
DEM prior to treatment with 5-HPQ, the pattern of hemoglobin binding was also 
remarkably similar to the hemolytic response for GSH-depleted erythrocytes. The 
observation that 5-HPQ treated red cells could be "rescued" from hemolysis by reduction 
with DTT, which was shown to release hemoglobin from skeletal membrane proteins, 
further supported a direct role for hemoglobin, or at least some redox sensitive protein, 
binding to skeletal membrane protein in the hemolytic response from 5-HPQ. 
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These findings are consistent with the hypothesis that 5-HPQ-exposure results in the 
formation of hemoglobin thiyl radicals, which first react with and deplete reduced GSH, 
and then react with a variety of sulfhydryl-containing structural proteins to form 
hemoglobin adducts to integral membrane and cytoskeletal proteins. Although, it could 
be that intracellular oxidative damage might directly alter reactive cysteines in Band 3 
that leads to "Band 3 clustering" and subsequent with subsequent antibody recognition 
(Turrini et aI., 2003). Regardless, additional studies are necessary to determine the 
precise internal protein targets that lead to an external signal for splenic sequestration. In 
view of the hypothesis that hemoglobin binding to numerous red cell skeletal membrane 
proteins is directly involved (Fig. 4.4B), it is likely the case that most of the binding of 
Hb would represent a bystander event. From Fig. 4.4A, it appears that members of the 
band 3 macrocomplex, specifically ankyrin and band 4.2, might be targets, and future 
experiments to identify specific inside-out protein alterations may involve the targeting 
hemoglobin for immunoprecipitation with subsequent mass spectral identification of 
bound proteins. Alternatively, biotinylation of cell surface amines, with subsequent 
avidin-column or gel isolation and identification of red cell surface proteins from 5-HPQ-
treated red cells could be used to examine external cell-surface alterations. 
Role for macrophages in the uptake of 5-HPQ treated erythrocytes 
An examination of the literature reveals that the removal of damaged or senescent red 
cells from the circulation by macrophages in the spleen that is often taken for granted 
despite the sparcity of specific evidence. Thus, we examined the fate of 5-HPQ-treated 
red cells and demonstrated for the first time that they are taken up exclusively by the 
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spleen. Additionally, we demonstrated that it is the resident macrophages that are 
specifically responsible for the uptake of red. Furthermore, we developed an in vitro 
erythrophagocytosis assay using the J774A.l macrophage cel1line, which, in addition to 
suggesting that uptake by macrophages is signal-dependent rather than dependent on 
Heinz body trapping within the splenic cords, provides us with a very useful tool that can 
be used to identify specific cell-surface alterations that are responsible for macrophage 
recognition. 
Studies to further validate and characterize our erythrophagocytosis assay are 
ongoing, and we are examining its ability to correlate with the specific effects that we 
previously observed in vivo. Specifically, depletion of GSH from red cells with DEM 
prior to treatment with 5-HPQ was shown to enhance red cell removal from the 
circulation of rats in vivo (Fig. 2.10), and we wanted to know whether depletion of GSH 
from red cells prior to treatment with 5-HPQ would enhance their erythrophagocytosis by 
J774A.l macrophages in vitro as well. Figure 3.7 showed that phagocytosis of red cells 
treated with a subhemolytic concentration of 5-HPQ (25JlM) was significantly enhanced 
in GSH-depleted versus GSH-normal rat red cells, and preliminary results suggest that 
the ability of DTT to "rescue" 5-HPQ-treated erythrocytes in vivo after in vitro exposure 
(Fig. 4.8) can also be reproduced using J774A.l macrophages in vitro (Fig. 5.4). 
One of several future directions that could be pursued using the erythrophagocytosis 
model in vitro involves the use of a fusion protein, which displays the extracellular 
domain of CD47 in order to restore proper recognition of "self' to the macrophages and 
specifically inhibit phagocytosis. Additionally, use of J774A.l macrophages could 
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Fig. 5.4. Effect of DTT on the phagocytosis of rat 51Cr-labeled erythrocytes after 
exposure to 5-HPQ (50IlM) by J774A.l macrophages in vitro (preliminary data). The red 
cells were incubated with or without 5mM DTT for 1 hr at 37°C after treatment with 5-
HPQ (20 or 40 min), or with vehicle (H20) alone (40 min) at 37°C. The erythrocytes 
were then washed and allowed to incubate with plated macrophages for 18 hr. After the 
incubation period, non-ingested red cells were lysed with NH4Cl and the macrophages 
extensively washed. Erythrophagocytosis was measured as radioactivity in macrophages 
(cpm). Data points are means ± S.D. (n=6) *, statistically significant, p<O.05. 
143 
would provide a model for examining concentration ranges of hemotoxic drugs, which 
result in phagocytosis by macrophages. Thus drug-induced biochemical alterations in 
human red cells could be studied within the context of drug concentrations that have been 
shown to be toxicologically relevant. Until now, one major problem with studying the 
effects of any hemolytic drug in human red cells is that there are no ethical or practical 
methods available that are equivalent to the in vitro exposure/ in vivo survival rat model 
to examine whether specific concentrations are toxicologically relevant, i.e. directly 
hemolytic, in humans. 
Conclusion 
Evidence has been presented in this dissertation to show that the phenolic primaquine 
metabolite, 5-HPQ, could play an important role in the overall hemotoxicity of the parent 
drug. While 5-HPQ is the most potent metabolite that has been examined in our 
experimental model, the determination of its relative contribution to the overall toxicity 
of primaquine will be dependent on its relative rate of formation, which has yet to be 
measured. However, in light of its potency, it is clear that in addition to being an 
important compound to study primaquine-induce hemolytic anemia, 5-HPQ can provide a 
useful tool that for studying the mechanism of hemolytic anemia and uptake of damaged 
cells in general. 
Our working hypothesis is shown in Fig. 5.5. Specifically, (1) 5-HPQ is thought to 
passively diffuse into cells, where the coordinated iron in hemoglobin catalyzes a redox 
cycle between 5-HPQ and its quinoneimine. Reactive species are generated which non-
specifically attack macromolecules in the vicinity of their formation. (2) Since red cells 
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are packed with hemoglobin, and ROS are formed intracellularly within the cytoplasm, 
hemoglobin is likely the primary target of oxidative damage. (3) It is thus thought that 
hemoglobin free thiols are activated to reactive thiyl radical intermediates, which are 
initially quenched by cellular reduced GSH, but then rapidly overwhelm this defense 
mechanism as radicals are formed faster than GSH is able to regenerate. (4) In the 
absence of sufficient GSH, hemoglobin thiyl radicals are free to attack other cellular 
targets, and our evidence suggests that hemoglobin binds non-specifically to free thiols 
on the cytoplasmic side of cytoskeletal and integral membrane proteins. (5) This addition 
of large protein adducts likely leads to specific cell surface alterations and/or loss of 
normal protein-protein interactions effecting a loss of recognition of "self' by splenic 
macrophages and subsequent phagocytosis. 
In summary, the data presented in this dissertation has lead to the postulate of a 
mechanism by which quinoneimine-type metabolites of primaquine might lead to the 
hemolytic removal of red cells. While there are remarkable similarities to the mechanism 
of removal induced by hydroxylamine-type metabolites, the mechanism presented in this 
dissertation also differs significantly. It is believed that the novel evidence presented 
provides additional and important insight into the mechanism( s) of drug-induced 
hemolytic anemia normal red-cell senescence. Additionally, we hope that the additional 
information provided regarding of the mechanism by which primaquine might mediate its 
toxicity will eventually allow for the rational redesign of the primaquine molecule, in 
order to significantly lessen its toxicity while maintaining its therapeutic efficacy. 
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